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ABSTRACT 
Receiving a cancer diagnosis is an extremely stressful life event. Cancer patients have been 
reported to experience an excessive risk of stress-related health outcomes including suicide. 
The time period between the first suspicion of a potential cancer and cancer diagnosis or start 
of primary cancer treatment is commonly defined as “cancer diagnostic workup”. This critical 
time window is especially stressful, mainly due to the uncertainty about the final diagnosis. 
Such diagnostic process and its health consequences may also apply to a larger group of 
population who are evaluated for but never receive a cancer diagnosis. Till now, less attention 
has been devoted to the health impact of a cancer diagnostic workup. This thesis aims to assess 
the risk of different stress-related health outcomes during a cancer diagnostic workup, taken 
into account various diagnostic processes, individuals with or without a final diagnosis of 
cancer, and different reasons of workup initiation. We also investiagated effect of a potential 
treatment in modulating the excessive risk of stress-related health outcomes following a cancer 
diagnosis.  
In study I, we examined the risk of iatrogenic and non-iatrogenic injuries during weeks before 
and after diagnosis among all patients with cancer. To eliminate impact of shared risk factors 
between cancer and injuries, we compared the risk from 16 weeks before to 16 weeks after 
cancer diagnosis, to the same period one year earlier, of the same patient. We found that cancer 
patients had an increased rate of both iatrogenic and non-iatrogenic injuries requiring inpatient 
care shortly before and after cancer diagnosis, compared to one year before. Our findings shed 
further light on the total burden of medical complications and call for prevention of intentional 
and unintentional injuries during the diagnostic process of a cancer. 
In study II, we assessed the risk of injuries that required inpatient care in relation to the 
diagnostic workup of cervical cancer and its precursor lesions, among all women that 
participated screening for cervical cancer. Women diagnosed with invasive cervical cancer 
and its precursors lesions were identified from the National Cervical Screening Register as 
exposed to a diagnostic workup. Women who had a normal result in Pap smear were 
classified as referece group. Inpatient care of either iatrogenic injuries or non-iatrogenic 
injuries was extremely rare during the diagnostic procedures of cervical cancer and its 
precursor lesions. Although with a small number of outcomes, we still found that women 
with invasive cervical cancer had an increased rate of non-iatrogenic injuries in relation to 
receiving a diagnosis of cervical cancer.  
In study III, we investigated the risk of psychiatric disorders and cardiovascular diseases 
during the diagnostic workup of potential breast cancer. All women diagnosed with a breast 
cancer, a benign tumor in breast, or unspecified lump in breast, were identified and 
considered as exposed to a diagnostic workup of potential breast cancer. We compared the 
risks of psychiatric disorders and cardiovascular diseases during the six weeks before 
diagnosis of the exposed women to the risks among the unexposed women. We found that 
women with benign tumor and breast cancer had an increased rate of psychiatric disorders 
and cardiovascular diseases while waiting for the final diagnosis. 
In study IV, we aimed to assess the use of low-dose aspirin and non-aspirin NSAIDs in relation 
to the risk of unnatural death due to suicide or accidents among patients after receiving a cancer 
diagnosis. Cancer patients with aspirin or non-aspirin NSAIDs dispensed after diagnosis were 
considered to be medicated. We compared the risk of unnatural death during on-medication 
period with the risk during off-medication period. We found that aspirin intake was associated 
with a lower risk of unnatural death after a cancer diagnosis. We did however not find a 
statistically significant association between use of non-aspirin NSAIDs and risk of unnatural 
death. 
In conclusion, a cancer diagnostic workup is associated with increased risks of a spectrum of 
stress-related health outcomes. Such increased risks of health outcomes, including injuries, 
psychiatric disorders and cardiovascular diseases, are noted for a large group of individuals 
being evaluated for a potential cancer, regardless of the final diagnosis. It represents therefore 
a great disease burden for the society. Interventions, such as low-dose aspirin intake, might be 
effective in reducing such risks (e.g. risk of unnatural death), after cancer diagnosis. 
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1 INTRODUCTION 
Stress and stress response to cope with changes in surroundings are common in daily life. 
Normal stress response is triggered by a stressor, a stimulus that can disrupt or threaten 
homeostatic balance, and is positive in most cases to adapt to changed situation, known as 
“eustress”. When stressors become excessive to adapt to, they can be harmful and affect 
psychical and mental conditions (termed as “distress”), resulting in stress-related health 
outcomes. Common signs of stress overload include, although not limit to, anxiousness, 
fatigue, insomnia, headache, poor concentration, negative thoughts, social isolation, etc.  
Receiving a cancer diagnosis is, among others, an extremely stressful life event. Compared 
with other patients, cancer patients have a higher burden of morbidity and mortality (1), largely 
attributed to the complex pathophysiology of the underlying malignant disease, the side effects 
of different cancer treatments, or simply the burden of having a progressing and fatal disease. 
Recently, cancer patients have been recognized to experience a wide spectrum of stress-related 
health outcomes, ranging from depression, anxiety, to severe outcomes such as acute 
cardiovascular events and suicide (2). Although the number of patients living with a cancer is 
increasing worldwide (3), the experience and its impact of psychological stress on patients with 
a cancer has not been fully investigated.  
Psychological stress can be measured directly by level of stress hormones in bio-samples, self-
reported measurements on stress symptoms, or questionnaires assessing stress experience and 
stress resilience (4). Besides, psychological stress can also be evaluated by assessing stress-
related health outcomes, as proxies to quantify its impact on patients who perceive a stressor. 
A comprehensive assessment of stress-related health outcomes among cancer patients from 
clinical evaluation to diagnosis and treatment has rarely been performed. Further, whether a 
potential intervention can attenuate the excessive risk of stress-related health outcomes in 
relation to cancer, is of great clinical importance.  
Therefore, the purpose of this thesis is to enhance the understanding of the impact from 
psychological stress on various stress-related health outcomes among patients being evaluated 
for a cancer, and to explore the potential effect of anti-inflammatory treatment in reducing such 
health outcomes, by taking the most advantage of the large population and health registers in 
Sweden. Findings obtained from this thesis may assist the healthcare providers, the families, 
and the society at large, in providing proper support, not only after cancer diagnosis but also 
during the clinical evaluation of a potential cancer.  
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2 BACKGROUND 
2.1 PSYCHOLOGICAL STRESS AND CANCER DIAGNOSIS 
2.1.1 Cancer diagnosis - a stressful life event 
The detection and treatment of cancer at early stage of disease progression improves short- and 
long-term survival. For many cancers, the prognosis and survival of patients with small size 
and localized tumor is generally better than those with advanced or metastatic tumor (5). Apart 
from the late onset of cancer symptoms, delay in referral to disease evaluation, diagnosis and 
treatment, can as well have considerable adverse health impact. It has been noted that longer 
delay in time between onset of symptoms and start of treatment was associated with advanced 
tumor stage and higher morbidity and mortality (6–8), although some found the association to 
be less clear or null (9,10). A recent systematic review found an evident association between 
shorter waiting time to diagnosis and better clinical outcomes in patients with cancers of breast, 
colorectal, head and neck, testicular and melanoma (11). 
In order to improve the variations in cancer survival and other comorbidities attributed to the 
delay in referral in cancer care, many countries start to establish comprehensive national cancer 
guidelines (12–15). In Denmark, a better survival and reduced mortality was reported among 
symptomatic cancer patients after the implementation of the Danish Cancer Patient Pathways 
(16). In Sweden, an investigation of national cancer strategy stated a lack of comprehensive 
review of waiting time in cancer care and a dissatisfaction among patients regarding 
organization and information delivery (17). To measure waiting time in cancer care, a model 
was established to cover the initial parts of the care path from referral decision to treatment 
start, with focus on patients’ perspective (Figure 2.1).  
Figure 2.1 Cancer pathway through care – model for measuring waiting time in Sweden, translated from report 
Vänterider i cancervården from the Swedish National Board of Health and Welfare (18). 
         
Based on this model, the Swedish National Board of Health and Welfare conducted a 
measurement of waiting time in cancer care, from referral decision until the start of treatment, 
for the most common cancer types (18). In this report, there was a discrepancy in the waiting 
time according to cancer characteristics as well as across regions. Patients diagnosed with 
advanced tumor stage had shorter waiting time than other patients, indicating that these patients 
were prioritized in the care system. The median waiting time was up to one month from 
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referral-to-specialist to treatment for all forms of cancer, except for prostate cancer. For patients 
with kidney cancer, rectal cancer and head and neck cancer, the median waiting time was close 
to two months (Table 2.1).  
Table 2.1 Waiting time from referral decision until the start of treatment for the most common cancer types in 
Sweden, report from the Swedish National Board of Health and Welfare, 2015 (19). 
Cancer type Median waiting time in days (1st – 3rd quarters)  
Breast cancer 20 (13-28) 
Skin melanoma 37 (23-58) 
Head and neck cancer 50 (35-70) 
Lung cancer 30 (15-50) 
Stomach cancer 20 (10-36) 
Esophageal cancer 19 (11-35) 
Kidney cancer 64 (42-104) 
Prostate cancer Remote metastatic: 43 (20-71) Intermediate and high-risk prostate cancer: 167 (125-223) 
Colon cancer 42 (29-60) 
Bladder cancer 36 (22-55) 
Rectal cancer 56 (43-78) 
 
Starting from 2015, to ensure equitable and accessible cancer care, the Swedish government 
has introduced standardized care pathways for different cancers. The purpose is to shorten 
unnecessary waiting time, reduce regional differences, provide better information, and to have 
more coherent care process and generally more satisfaction in cancer care for all patients (20).  
2.1.2 Cancer diagnostic workup 
Studies have predominantly investigated the health impact of waiting time to diagnosis and 
treatment on cancer survival (11). However, less attention is devoted to potential health risks 
during the time period from the first suspicion of cancer to start of treatment (commonly 
defined as “cancer diagnostic workup”). A cancer diagnostic workup usually starts when 
patients first contact with healthcare or participate in cancer screening, through referral 
decision, specialist visit, diagnosis, until the start of treatment (Figure 2.1). Primary treatment 
commonly includes surgery, radiotherapy, chemotherapy, and combined with other therapies 
(hormonal therapy, immune therapy, etc.), according to tumor characteristics and patients’ 
conditions. 
Evidence has nevertheless started to accumulate suggesting that the workup of a potential 
cancer, together with the treatment consequences, induces severe emotional turmoil that might 
result in significant health problems (21,22). The health impact of cancer diagnostic workup is 
not only pertinent to patients who are eventually diagnosed with cancer, but also to individuals 
who are evaluated for but do not have a cancer diagnosis. So far, knowledge about the precise 
population size of individuals who have been suspected for cancer but do not receive a cancer 
diagnosis is limited. In the United States, less than 20% of the children and teenagers who were 
evaluated for a potential cancer received eventually a cancer diagnosis and subsequent 
treatment, indicating that over 80% of the cancer workups were exploratory and did not result 
in a diagnosis of cancer (23). For adults, the proportions of verified cancer cases among primary 
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healthcare referrals for suspicious cancers appear to vary widely for different cancer types, 
from 3-11% for breast cancer (24), 25% for prostate cancer (25), and 60% for skin cancers 
(26,27). Moreover, the recent advancement in early cancer detection (e.g., via various screening 
activities) has the potential of introducing cases with false-positive test result and the 
subsequent over-treatment of cancer, which may further contribute to the extra burden in cancer 
care (28,29). 
2.1.3 Health outcomes related to cancer diagnostic workup 
2.1.3.1 Stress-related health outcomes 
A diagnostic workup of cancer was found to clearly affect health and well-being, particularly 
psychosocial functioning. Affected domains might vary for different cancers, but generally 
include distress, fear and worry about having or getting a cancer, anxiety, mood changes, sense 
of uncertainty, disturbances in family, social and sexual roles, behavioral symptoms such as 
crying, sleep disturbance, and irritability, concerns about future reproduction (28,30,31). 
Researchers from the UK had extensively measured psychological distress along the diagnostic 
workup in men being evaluated for prostate cancer using questionnaires (21). More than half 
of patients scored waiting for biopsy result as the most stressful event, in contrast with only 4% 
that reported the procedure itself to be most stressful (21). To date, few studies have addressed 
the risks of concrete health outcomes related to psychological stress during a cancer diagnostic 
workup, although such impact is increasingly suggested (21,30,32). 
Psychiatric disorders 
Psychiatric disorders, in particular, depression, are commonly recognized health outcomes 
among cancer patients. In oncological settings, the prevalence of all types of depression is about 
20% (33), and is significantly higher compared with a prevalence of 5-9% in general population 
(34,35). The prevalence of having any mood disorder is even higher, i.e., around 40% (33). It 
has been noted that children undergoing a diagnostic workup of cancer and their parents had 
an increased risk of anxiety and depression (23). In adults, an increased risk of hospitalization 
for depression was reported after a cancer diagnosis, mainly during the first year following a 
diagnosis (36). Such risk increase remained during the subsequent years for most cancer types 
(36). A recent study investigated the risk of any mental disorder among cancer patients, and 
demonstrated an increased risk of mental disorders starting from one year before cancer 
diagnosis onward (37). The risk elevation during the year before cancer diagnosis was 
speculated as a result of cancer symptoms and severe psychological distress experienced during 
clinical evaluation of a suspected cancer (33). However, few studies have assessed the risk of 
psychiatric disorders during the process of clinical evaluation for cancer.  
Cardiovascular diseases 
Evidence has accumulated suggesting the link between psychological stress and cardiovascular 
morbidity and mortality (34,35). Psychological distress experienced in daily life has been well 
established to be associated with the acute onset of cardiovascular diseases, such as myocardial 
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infarction and cardiac events (36,37). Higher risks of cardiovascular comorbidities have also 
been increasingly recognized among cancer patients (38). Cardiovascular conditions and 
hypertension are the most frequently identified comorbidities among cancer patients (39). More 
and more studies reported a higher rate of deaths from non-cancer causes among cancer patients 
than cancer causes, with cardiovascular disease as the leading cause of non-cancer mortality 
(1). The increase in risk of cardiovascular deaths was highest during the first weeks after cancer 
diagnosis and remained elevated, although with declining magnitude over time, during the first 
year after diagnosis (22,40,41). In addition to fatal outcomes, an increased risk of 
hospitalizations due to venous thromboembolism was reported among cancer patients, 
compared to the general population (42). The risk increase was more prominent for patients 
with metastatic tumors compared to other patients (41). The physical burden of a progressing 
disease, the cancer treatment, and the psychological distress induced by the cancer diagnosis, 
might collectively contribute to the risk increase. To date, evidence is still limited in 
understanding the risk of cardiovascular diseases before cancer diagnosis, especially when the 
patients are evaluated for a potential cancer. 
Intentional injuries 
Intentional self-inflicted injuries, such as suicide, are common among cancer patients (43). The 
prevalence of suicidal behaviors in general was estimated to be around 30% among patients 
with cancer (44,45). Cancer patients have around two times higher rate of suicide, compared 
to the general population (45). A large population-based cohort study found a 12-fold risk 
increase of suicide during the first week after cancer diagnosis, and the risk attenuated but 
remained increased during the first year after cancer diagnosis (22). Similar risk increase has 
thereafter been reported from many countries (46–48), both among young and adult cancer 
patients (40,41,49). Studies have provided evidence showing a greater risk increase of suicide 
among male and older patients, and patients with depression, advanced tumor stage or 
metastatic disease, as well as patients who were recently diagnosed with cancer (43,45,46). 
Although large proportion of cancer patients with suicidal ideation were reported to have major 
depression (50), the relative risk of suicide was higher among patients without such 
comorbidity (22). This is possibly be explained by the lower risk of suicide among individuals 
without depression. More studies are needed to explore the impact of cancer-related 
psychological stress on self-inflicted injuries, for instance, by focusing on non-fatal outcomes 
during clinical evaluation for a cancer.  
Unintentional accidents 
Besides deliberate self-harm, other external caused injuries or accidents, are common health 
outcomes among the elderly, representing a major health burden in old population. It was 
estimated that around 27% of the old adults fell at least once per year (51), among which, 10% 
might be severe injuries including fractures, joint dislocations and concussions (52). Despite 
being a common health outcome, such injuries are less investigated in cancer patients. 
Recently, a study from the UK investigated the association between hospital admissions and 
deaths due to self-harm and accidents within five years after cancer diagnosis, reporting an 
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increased risk of fatal and hospitalized accidents (53). The number of accidental outcomes was 
truly greater than suicide (53). An increased risk of death due to accidents was further identified 
during the first year after cancer diagnosis (47,54). Shared patient characteristics exist between 
suicide and accidental deaths, including physical, social and emotional dysfunctions (55). It 
was evident that depressive symptoms are risk factors for accidents such as falls and suicidal 
outcomes (56). Considering the absolute risk of the outcomes, the burden of accidents is of 
great public health importance and a potential threat to cancer patients’ quality of life. 
However, evidence is scarce regarding the impact of a recent cancer diagnosis or cancer 
diagnostic workup on such injuries. 
To conclude, being diagnosed with cancer stands for a fundamental challenge for cancer 
patients, both physically and psychologically. There is a great burden of different stress-related 
health outcomes among cancer patients (43). As the majority of attention is being paid to the 
later phase of the disease course, more knowledge is needed to better understand the health 
impact of cancer diagnostic workup, in addition to the eventual diagnosis, treatment and 
survivorship. 
2.1.3.2 Other health outcome- Iatrogenic injuries 
Cancer diagnostic workup is a period of time overwhelmed by a sequence of intensive medical 
examinations as well as subsequent treatment. Individuals evaluated for a potential cancer have 
more opportunities to be exposed to medical procedures and biological substances, and are 
more likely to suffer from iatrogenic injuries. Iatrogenic injuries can be defined as the 
unintended act from care process that might cause harm to the patients, and can also be referred 
to as medical complications, medical error or medical adverse events. Such injuries are 
estimated to be the third leading cause of death in the United States (57). However, the statistics 
of these injuries in general is limited. 
Although systematic assessment in cancer patients is lacking, evidence has nevertheless 
suggested high burden of iatrogenic injuries among patients with severe illness. In a sample of 
randomly selected hospitals, the adverse events related to medical care were reported in 3.7% 
of hospitalized patients, including mostly temporally disabling injuries but also permanently 
disabling injuries (2.6%) and death (13.6%) (59). A medical record review study revealed that 
16.6% of hospital admissions were associated with an adverse event resulting in disability or a 
longer hospital stay, of which, 13.7% were permanent disability and 4.9% were death (60). 
Human error was found to be the prominent cause (61). Wilson et al. reported that half of the 
medical adverse events occurred during surgery, and the others were diagnostic errors and drug 
complications (58,62). The rate of adverse events was higher among older, compared to 
younger, patients (59,63). Medical complications induced by human errors can be avoided, 
with 30-90% of adverse events estimated to be preventable (63–65). So far, the burden of 
iatrogenic injuries is not well identified among cancer patients, due to limited studies.  
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2.2 CERVICAL CANCER 
Cervical cancer represents the fourth most common cancer in women, with approximately 
570,000 cases and 311,000 deaths from cervical cancer in 2018 worldwide (66). The incidence 
of cervical cancer varies largely across countries. In Sweden, cervical cancer ranked as the 13th 
most common cancer in 2015, with a number of 563 new cancer cases and 163 deaths from 
this cancer (67). Great improvements have been achieved due to implementation of cervical 
screening. Nowadays, cervical cancer mostly affects women in less developed countries, where 
effective screening protocols are yet in place. 
The most important risk factor and necessary cause of cervical cancer is the persistent infection 
with carcinogenic human papillomavirus (HPV) (68). HPV infection is common, with an 
estimated prevalence of about 11% in general population (69). Despite of the pivotal role of 
HPV infection on the formation and progression of cervical precursor lesions, most infection 
can be cleared and suppressed by human immune system within 1-2 years (70). About 10% of 
the infection can persist for years and are highly correlated with the development of cervical 
cancer and cancer precursors (70). Other risk factors, including smoking (71), hormonal 
contraception use (72), and risky sexual behaviors (73), may interact with HPV infection and 
contribute to carcinogenesis. It usually takes several years for cervical cancer to develop from 
precancerous lesions. The abnormal histological diagnoses include cervical intraepithelial 
neoplasia grade 1-3 (CIN 1-3), cervical adenocarcinoma in situ, and invasive squamous 
cervical cancer and invasive cervical adenocarcinoma. The precancerous lesions have the same 
potential to regress, to persistent, or to progress. A study of national history indicated that 1% 
of CIN1, 5% of CIN2 and 12% of CIN3 would progress to invasive cancer (74). Treatment 
such as surgery or chemo-radiotherapy could cure 80-95% of women with early stage cervical 
cancer and 60% with advanced stage disease (75).  
2.2.1 Screening for cervical cancer 
The cervical screening program is regarded as the most successful cancer screening program 
and has substantially contributed to reduced number of cancer incidence and mortality. The 
purpose of cervical screening is to reduce cancer incidence by early detection and early 
treatment of cancer precursors, and to improve the prognosis and to reduce mortality for 
invasive cancer (76). In Sweden, all women have been invited to organized screening for 
cervical cancer in a three-year interval (for those at age 23-50 years) or a five-year interval (for 
those at age 51-60 years) since 1970s. In addition to organized screening, opportunistic 
screening occurs when women seek for screening service instead of a planned test. The average 
participation rate in 2016 was around 82% for women who had participated in screening, 
among which, 70% happened in organized screening (77). The conventional cytology method, 
that is, the papanicolaou smear test (Pap smear), has been used for cervical screening. The 
cytological abnormalities determined by Pap smear can be managed by colposcopy, sometimes 
including a punch biopsy. The cervical screening has significantly improved the cure for 
cervical cancer. The cure proportion was 92% for screening detected women whereas 66% for 
symptomatic women (76), mainly due to detection of early stage disease and the asymptomatic 
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feature of screening detected cases. However, the detection of precancerous lesions in 
screening might also raise the concern about over-diagnosis and over-treatment, because not 
all lesions will advance to cancer eventually. 
2.2.2 Health outcomes during cervical cancer evaluation 
Despite the great health benefits entailed by cervical cancer screening, concerns for potential 
harms have also been raised. In addition to obstetric outcomes related to treatment procedures, 
psychological health outcomes might also be of relevance. During the diagnostic workup, 
women confront not only the fear of having a progressing disease, but also uncertainty of 
consequence of the disease (78). Due to the sexually transmitted nature of HPV and its link to 
cervical cancer, women screened with positive result might experience extra anxiety, social 
stigma, concerns of relationships, and worry of disclosing the result to the others (79). Women 
receiving an abnormal screening test result were indeed shown to have an increased risk of 
anxiety, distress, sleep disturbance and poor concentration (80–82). It was also recognized that 
colposcopy and its related procedures might lead to an increased level of anxiety and other 
psychological outcomes (80,82). Elevated psychological distress was also noted among women 
with low grade cytological lesions (83). Most of the previous studies were conducted in 
selected population and used questionnaires with self-reported information, which might limit 
the generalizability of their findings. To date, a comprehensive investigation is still lacking in 
quantifying concrete health outcomes, because patients and clinicians are more likely to 
underestimate the potential harms in cancer screening (84,85). Moreover, health problems such 
as bleeding, infection and adverse drug events were reported as a result of invasive diagnostic 
procedures and treatment (86). To what extent the health burden can be requires more 
investigations. 
2.3 BREAST CANCER 
Breast cancer is the most common cancer among women and the fifth cause of death from 
cancer (87). There was about 2 million breast cancer cases and 601,000 cancer deaths in 2017 
around the world (88). About one in eight to ten women will develop breast cancer during their 
lifetime (89). The median age at diagnosis was 61 (90), and the 5-year relative survival for 
breast cancer was around 80% (91). In Sweden, 9,382 patients were diagnosed with breast 
cancer in 2015, leading to an incidence of 192 per 100,000 person-years (67). Thanks to breast 
cancer screening and the advancement of cancer treatment, the mortality has substantially 
declined since the 1970s (92). Breast cancer is rare in men. Apart from being a female, the risk 
of developing breast cancer is highly correlated with advanced age as most breast cancer is 
diagnosed among women over 50. Mammographic density, referred as the white proportion of 
the mammogram, is another important risk factor for breast cancer. A systematic review and 
meta-analysis demonstrated that women with 75% mammographic density have almost five 
times risk of breast cancer, compared to women with less than 5% mammographic density (93). 
Abnormalities such as tumor tissues are more difficult to detect on a mammogram in dense 
breasts. Other risk factors include previous benign breast disease (94), family history (95), risk 
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genes (96), higher socioeconomic status (97), use of hormonal therapy (98), and alcohol 
consumption and obesity (99,100).  
Breast cancer often originates from cells in the milk-producing ducts (ductal carcinoma), less 
common in the glandular tissues known as lobules (lobular carcinoma) and in other tissues. 
Signs of breast cancer include a lump or change in the breast. The routine cancer screening and 
the improvement in diagnosis have led to an increased detection of early precursor lesions of 
the breast, including atypical ductal hyperplasia, flat epithelial atypia, atypical lobular 
hyperplasia and radial scar (101). Ductal carcinoma in situ was rarely diagnosed before 1980, 
but now accounts for 25% of newly diagnosed breast cancer (101). The certainty about which 
lesions will progress to cancer needs to be improved. A recent literature review reported 9-28% 
upgrade rates to breast cancer for different precursor lesions of the breast (102). Surgery is the 
primary treatment to remove tumor, combined or not combined with other treatments (radiation 
therapy, chemotherapy, hormone therapy, etc.). 
2.3.1 Screening for breast cancer 
The purpose of breast cancer screening is to identify breast cancer in early stage, where more 
treatment options and better treatment outcomes can be achieved. Screening for breast cancer 
with mammography results in controversial benefits. Although lower mortality rate due to 
breast cancer was observed after mammography screening (92,103), the debate is still ongoing 
about risks and benefits (28). Extending the screening age, or with shorter intervals are likely 
associated with greater mortality reduction and greater health benefits, however studies are yet 
to quantify the precise magnitude of benefits and the potential harms (104). 
In Sweden, women at age 40-69 years have been offered regular mammography screening 
since 1974 and it became nationwide since 1997 (105). Nowadays, women at age 40-74 years 
are invited for mammographic screening every 18-24 months, and the participation rate is about 
80% (106). In the screening settings, women with suspected imaging on a mammogram are 
referred for further investigation, usually including a combination of expanded mammographic 
imaging and ultrasound and when needed with puncture biopsy. Magnetic resonance imaging 
(MRI) is also possible at times. Despite of the consistent evidence showing the reduced 
mortality from breast cancer due to screening, the debate is ongoing considering the potential 
harms of screening with mammography, including false-positive results, negative 
psychological consequences, and over-treatment of cancers (28). 
2.3.2 Health outcomes during breast cancer evaluation 
Patients with breast cancer were reported to have a higher prevalence of psychiatric disorders 
compared to patients with other cancer types (107). Women with a newly diagnosed breast 
cancer were found to have an increased risk of psychiatric symptoms (108). A recent study 
reported an increased risk of depression, anxiety, and stress-related disorders among women 
with invasive breast cancer, with the highest risk increase shortly after diagnosis and remained 
elevated during five years after diagnosis (109). Apart from patients with invasive breast 
cancer, patients with in situ breast cancer had also an increased risk of stress-related disorders 
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during six months after diagnosis (109). The results on whether or not women with false 
positive mammography result have negative psychosocial consequence are controversial. In 
one study, psychological distress was found to persist for three years (110), whereas others 
argued that such psychological experience had no adverse effects on psychological functioning 
(111). Controversial findings were also noted in women receiving a clear result in screening 
(32,112).  
Compared to psychiatric disorders or symptoms, less is known regarding other health risks. A 
population-based study examined the long-term risk of suicide after diagnosis among breast 
cancer survivors in the United States, and found the highest risk increase during the first years 
after cancer diagnosis, although the elevated risk remained 15 years after diagnosis (113). 
Breast cancer patients have also been shown to have higher risk of cardiovascular death than 
general population (114,115). It was reported that breast cancer patients had more than 3-fold 
risk increase of developing venous thromboembolism compared to cancer-free counterparts 
(116), with particular risk increase in the first year after cancer diagnosis (42). In addition, 
breast cancer patients had more than 20% increased risk of death and hospital admission due 
to accidents within five years of diagnosis (53). These findings suggest that the immediate time 
period after cancer diagnosis is a critical time window for stress-related health problems. 
Complications, including bleeding and hematomas, infections, and pain, are also recognized in 
patients receiving a biopsy for cancer diagnosis (117). Given the large number of women 
suspected for a potential breast cancer, studies are needed to measure the impact of health risks 
during cancer evaluation process, for all women undergoing a diagnostic workup of potential 
breast cancer. 
2.4 INFLAMMATION – A COMMON PATHWAY OF STRESS-RELATED 
HEALTH OUTCOMES 
Stress response can provoke comprehensive neurochemical, neurotransmitter and hormonal 
alterations by predominantly activating the sympathetic nervous system (SNS) and the 
hypothalamic-pituitary-adrenal (HPA) axis (118). Recently, inflammation is proposed to be a 
new and promising biological mechanism linking together stress and stress-related health 
outcomes(119), providing a new opportunity for disease prevention. 
2.4.1 Inflammatory pathway 
Stress hormones, such as glucocorticoids, are the major hormones secreted by adrenal glands 
from HPA axis in stress response, and enhance the activation of immune system (120). The 
activated inflammatory response and inflammation can serve as a common pathway between 
stress and its subsequent health outcomes. The increase in proinflammatory cytokines is linked 
to a variety of symptoms, such as fatigue, anhedonia, cognitive impairment, social withdrawal 
and motor retardation, which are further associated with sickness behaviors and somatic 
diseases (121).  
Evidence has been accumulated showing an association between inflammation and psychiatric 
symptoms and disorders. Peripheral inflammation and neuroinflammation could play a pivotal 
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role in the initiation and progression of mood and psychiatric disorders (122), and among 
others, cardiovascular diseases (118). For example, activation of the immune system and its 
influence on the neurodevelopmental process are noted in animal models (123,124) and human 
studies (125,126). Positive association has been noted between depression and plasma 
inflammatory markers, with a dose-response relationship (127). Patients hospitalized for 
infection were found to have a 62% increased risk of mood disorder (122). Furthermore, 
cytokines are crucial for the normal functioning of the brain, and can intervene neurocircuitry 
and neurotransmitter systems (128,129). Psychological distress, together with its resultant 
psychiatric symptoms, might induce behavioral changes (43,130). The increased inflammatory 
cytokine levels might contribute to the development of depressive symptoms, which might 
further correlate with cognitive impairment and reduced motivation and motor activity 
(118,131). As a result, stress-induced cognitive impairment could be associated with risk of 
injuries, such as hip fracture and falls (132,133). Indeed, using a self-reported 
neuropsychological test, lower score in cognitive and motor function was found to be 
associated with the risk of falls among elderly people without dementia or mild cognitive 
impairment (133). However, these studies were limited to experimental or clinical settings, 
with highly selected samples. More studies are needed to enroll a larger group of heterogeneous 
population. 
Although the role of inflammatory pathway has been increasingly recognized as a pivotal 
molecular basis in the pathogenesis of many diseases (118), the mechanisms underpinning 
stress and stress-related diseases are still under debate. 
2.4.2 Anti-inflammatory medication as potential treatment approach 
Assuming an important role of inflammatory pathway in linking together stress and stress-
related health outcomes, the use of anti-inflammatory agents, such as nonsteroidal anti-
inflammatory drugs (NSAIDs), has been proposed as a potentially effective therapeutic 
strategy for stress-related health outcomes (134,135). The therapeutic potential of NSAIDs 
might involve cyclooxygenase (COX) enzymes including COX-1 and COX-2, which are 
essentials for prostaglandins involved in inflammation.  
NSAIDs are a variety of drugs with analgesic, anti-inflammatory and anti-pyretic effects (136). 
The potential utility of NSAIDs on stress-related health outcomes is still under debate. In one 
study, the outcome of major depressive disorder was not improved after use of NSAIDs (137). 
In another study, a decreased rate of incident depression was noted after continued use of low-
dose aspirin, while an increased rate was noted after the use of non-aspirin NSAIDs and high-
dose aspirin (138). Notably, a meta-analysis of randomized clinical trials suggested a promising 
effect of NSAIDs in reducing major depressive disorder by inhibiting proinflammatory 
cytokines, without increasing risks of adverse effects such as gastrointestinal and 
cardiovascular events (134). In addition to the conflict findings of aspirin use and cancer 
mortality (139,140), there remains a need to investigate the potential of aspirin and non-aspirin 
NSAID use on deaths from non-cancer causes.  
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3 AIMS 
The overarching aim of this thesis was to contribute to a comprehensive picture of health risks 
in relation to cancer diagnostic workup, by examining 1) risks of stress-related health outcomes 
related to the cancer diagnostic workup, and 2) the potential effect of anti-inflammatory 
medication use in modulating the excessive risks of stress-related health outcomes following a 
cancer diagnosis.  
Specifically, we aimed: 
• To examine the risk of hospitalization for injuries immediately before and after 
cancer diagnosis (Study I). 
 
• To examine the risk of hospitalization for injuries during the diagnostic workup of 
cervical cancer and its precursors (Study II). 
 
• To examine the risks of psychiatric disorders and cardiovascular diseases during 
the diagnostic workup of potential breast cancer (Study III). 
 
• To examine the association between use of NSAIDs and the risk of unnatural death 
due to suicide or accidents following a cancer diagnosis (Study IV).  
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4 STUDY MATERIALS 
4.1 SWEDISH POPULATION AND HEALTH REGISTERS 
Data used in each individual study was based on a variety of Swedish population and health 
registers.  
Swedish Cancer Register 
The Swedish Cancer Register includes all diagnoses of malignant tumors and certain benign 
tumors in Sweden since 1958. It is regulated by law that all healthcare providers must report 
any newly identified cancer to the register. The reporting to Cancer Register is commonly 
notified twice by physicians and pathologists separately to double confirm the cases. The 
completeness and reliability of cancer registration in the register is verified to be nearly 100% 
(141). Since 2004, the information on histology and tumor stage is largely available in the 
register. 
Swedish Cause of Death Register 
The Swedish Cause of Death Register collects nationwide information on all death certificates 
nationwide from 1961 onward, including dates and the underlying and contributing causes of 
death. It is compulsory to report all deaths to the register by law (142), by physicians in 
hospitals or medical examiners if death occurs outside of hospital. The causes of death have 
been validated with high accuracy and are considered as a valuable resources for medical 
research (142). 
Swedish Patient Register 
The Swedish Patient Register collects hospital discharge records with a coverage of 60% across 
the country since 1964/1965, and become 100% nationwide since 1987 (143). This register 
includes further outpatient visit from 2001 onward, with a coverage above 80% (143). 
Information such as admission and discharge dates, primary and secondary discharge diagnoses 
coded according to the International Classification of Disease (ICD) system, has been provided 
in the register. All diagnoses were coded according to the 7th Swedish revision of ICD codes 
(ICD-7 before the year 1969), in ICD-8 (1969 to 1986), in ICD-9 (1987 to 1996), and in ICD-
10 (from 1997-). This register has been validated for a variety of diseases and is considered as 
a reliable source for research use. In the Patient Register, diagnoses of injuries are mandatory 
to be reported with corresponding external causes, and the completeness of such information 
is above 90% (143). 
Swedish Prescribed Drug Register 
The Swedish Prescribed Drug Register contains information on all prescribed and dispensed 
medications from all Swedish pharmacies from July 2005 onward (144). It includes 
information on medicine types, prescription and dispensing dates, quantity, defined daily dose, 
and prescription text updated for each dispense (144). All medicines recorded in the register 
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have been classified according to the Anatomical Therapeutic Chemical (ATC) system (145). 
Prescription for medication use is commonly renewed once a year and dispensed for up to a 
three-month supply in Sweden. The implementation of this prescribed drug register has been 
regarded as a great opportunity to explore effectiveness of drug use on various health risks.  
Other population registers 
The Total Population Register is regularly updated by Statistics Sweden (SCB). It includes 
information on date of birth, socioeconomic status, cohabitation status, registered address, 
migration and death for all residents from 1960s (146). A national population and housing 
census was conducted every five or ten years through questionnaires, collecting information 
on employment, household composition and accommodation until 1995, which was then 
replaced by a completely register-based approach (147). The Longitudinal Integration 
Database for Health Insurance and Labor Market Studies (LISA in acronym) has collected 
information on cohabitation status, income, employment and education from labor market, 
educational and social sectors for all residents at age 16 and above in Sweden, and is updated 
every year since 1990. Same information can also be obtained from other registers, for instance, 
education level from the Education Register.  
4.2 SWEDISH NATIONAL CERVICAL SCREENING REGISTRY (NKCX) 
Cervical screening was organized and implemented on county level in Sweden in late 1960s. 
The NKCx is a quality register for cervical cancer prevention. It has since the 2002 saved all 
data on screening test and diagnostic results across the country. Large part of screening test 
results is from planned test for healthy women for screening purpose, and data is also included 
for women with suspected changes under investigation. The NKCx comprises information 
including cytology test results from Pap smears, histology results from punch biopsies, and 
treatments for those in need (148). The coverage of cytology tests increased over time and 
reached almost 100% in 1993; a full coverage of histology tests was also achieved in 1993 
(148).  
4.3 SKÅNE HEALTHCARE REGISTER (SHR) 
Skåne is the southernmost region in Sweden, covering about one-eighth of the Swedish total 
population (~1.3 million residents) (149). All individuals residing in this region can actively 
choose to be enrolled in a primary care center, or automatically be assigned to the nearest 
primary care center according to residential area. All medical records have been entered by 
healthcare providers and automatically transferred to the Skåne Healthcare Register (SHR) 
since 1998. The SHR includes data from all levels of healthcare (either public/private sectors, 
primary, specialist or hospitalizations), including type of healthcare professional, date of visit, 
diagnostic codes, and surgical or non-surgical codes. The coverage is around 100% for 
inpatient care, and has increased to over 90% for secondary outpatient care after 2010 (150). 
The proportion of physician visits in primary care with an assigned diagnosis was approaching 
100% over time (Figure 4.1). The accuracy of recorded diagnoses was validated and considered 
  17 
to be of good quality for research (150). Healthcare provided outside Skåne for residents in this 
region usually requires restricted permission and is believed to be at a negligible level. 
                           
Figure 4.1 Proportion of physician visits that have an assigned diagnosis, 1998-2017 (150). 
 
Table 4 Overall view of registers used in studies. 
Register Source Content Study 
Swedish Cancer Register Socialstyrelsen Cancer diagnosis Study I, II, III, IV 
Swedish Cause of Death Register Socialstyrelsen Death Study I, II, III, IV 
Swedish Patient Register Socialstyrelsen Clinical diagnosis Study I, II, IV 
Total Population Register SCB Total population, 
migration 
Study II, III 
Swedish Education Register SCB Education level Study I  
Swedish population and housing census SCB Cohabitation status, 
occupation, region 
of residence 
Study I 
The Longitudinal Integration Database for 
Health Insurance and Labor Market Studies 
(LISA) 
SCB Education, income, 
cohabitation status 
Study IV 
Prescribed Drug Register (PDR) Socialstyrelsen Dispensed 
medication 
Study IV 
Swedish National Cervical Screening 
Registry  
NKCx Cervical screening Study II 
Skåne Healthcare Register (SHR) Region Skåne All levels of 
healthcare visits in 
Skåne 
Study III 
 
4.4 ETHICAL CONSIDERATION 
Our register-based studies largely relied on information retrieved from population and health 
registers, which raised the concern of how to protect sensitive data, such as medical records 
and personal information. According to Swedish regulation, informed consent from each 
individual is not required for research purposes when using national registers, given that an 
ethical permit is granted by ethical review board upon study initiation (151). All studies include 
in this thesis were approved by the Regional Ethical Review Board in Stockholm (EPN 
2015/1574-31). The informed consent from individual level was therefore waived in all studies. 
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The personal identification number (PIN) is uniquely assigned by the Tax Agency to each 
resident after birth or immigration. The PIN was replaced by a study-sensitive identifier during 
data linkage conducted by the National Board of Health and Welfare and Statistics Sweden. 
All linked data were delivered under strict protection and stored safely on server in the host 
institution with limited access. Moreover, research findings are communicated on aggregated 
level, in tables, figures and text. No case was individually discussed. Therefore, sensitive data 
was anonymous and handled safely during the entire research process.  
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5 STUDY DESIGN AND METHODS 
5.1 INJURIES AROUND CANCER DIAGNOSIS (STUDY I) 
5.1.1 Study design and participants 
Based on the Swedish Cancer Register, we identified in total 740,114 individuals with a first 
cancer diagnosed between 1991 and 2009. All cancer patients were cross-linked to the Swedish 
Cause of Death and Patient Registers by using the uniquely assigned PIN to all Swedish 
residents. We classified all cancer patients into common cancer types by using the 7th Swedish 
revision of ICD codes. Smoking and drinking alcohol are two lifestyle factors that are related 
to both the risks of cancer and injuries (152,153). We therefore additionally classified cancers 
of mouth, nasopharynx, oesophagus, pancreas, lung, kidney, bladder and urinary tract as 
smoking related cancers, and classified cancers of mouth, larynx, oesophagus, biliary duct and 
liver as alcohol related cancers.  
Table 5.1.1 Numbers of cancer patients according to cancer types. 
Cancer types ICD-7  Number of individuals 
any cancer  140-209 740,114 
prostate cancer  177 123,837 
breast cancer (female only) 170 101,458 
colorectal cancer  153,154 84,527 
non-melanoma skin cancer 191 33,409 
lymphatic and hematopoietic cancer 200-207 52,266 
lung cancer  162, 163 49,491 
cancers of central nervous system 193 21,199 
“severe cancers” including cancers in oesophagus, 
liver, and pancreas 
150,155,156,157 220,087 
   
smoking related cancers  140,141,150,157,180,181,143-
149,160-162 
116,501 
alcohol related cancers 141,155,161,143-146,148-150 29,511 
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Figure 5.1.1 The flowchart and design of Study I. 
 
5.1.2 Definitions of time periods 
The Swedish Cancer Register provides no information on the start of clinical evaluation for a 
cancer. However, it was reported that the median waiting time from the first referral to a 
specialist for suspected cancer and the primary treatment, was around two months during the 
study period in Sweden (18). The waiting time varied largely between different cancer types. 
Because the initial contact with healthcare provider, as well as the symptoms of cancer, likely 
start much earlier than the first specialist visit, we therefore defined the diagnostic period as 
the time interval from 16 weeks before to 16 weeks after the date of cancer diagnosis, 
presumably covering the routine cancer diagnostic process through the primary treatment in 
Sweden. We defined the same 32 weeks one year before date of cancer diagnosis as the 
reference period (“pre-diagnostic period”). To compare with the risk increase after diagnosis, 
we further defined the same 32 weeks one year after date of cancer diagnosis as the post-
diagnostic period, among patients that were alive one year after diagnosis (N=581,954). 
To eliminate the shared risk factors between cancer and injuries, in this study, we used a within-
individual comparison design, namely to compare the risk of injuries during the diagnostic 
period or post-diagnostic period with the risk during the pre-diagnostic period prior to cancer 
diagnosis, for the same patient.  
5.1.3 Ascertainment of injuries 
Injuries were ascertained using ICD codes in two ways: 1) “injury diagnosis codes” which 
describe the body and nature of an injury, and 2) “external cause of injury codes, or E-codes” 
which describe the cause and intent of an injury (154). The E-codes were first developed in 
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ICD-9, as a supplementary classification, and were intended to be used in addition to “injury 
diagnosis codes”. The E-codes should provide additional information on multiple conditions, 
classifying the cause of injury based on the environmental events, circumstances and other 
adverse effects (155).  
In Study I, all hospitalized injuries during the pre-diagnostic, diagnostic and post-diagnostic 
periods, were identified from the Swedish Patient Register using ICD-9 (1991-1996) and ICD-
10 (1997-2010) codes. We separated iatrogenic and non-iatrogenic injuries by using both the 
injury diagnosis codes and E-codes, throughout the analyses. Injuries related to medical actions 
(diagnosis, treatment, etc.) or other medical complications were referred to as iatrogenic 
injuries. Other injuries that were not associated with medical procedures or health seeking 
behaviors of the patients, were designated as non-iatrogenic injuries. We further classified 
iatrogenic injuries into drug-related and medical intervention-related injuries. Non-iatrogenic 
injuries were classified by nature, region, mechanism, place of occurrence, and manner of 
intent, according to the injury diagnosis codes or E-codes. The ICD codes used for the 
classification are listed in Table 5.1.2. 
Repeated events of injuries were taken into account because one patient could contribute 
multiple times the diagnoses of injuries. We therefore considered consecutive hospital 
discharges within one week, or with the same injury diagnoses, as one injury event (18.7%). 
Because fatal injuries were not possible during the pre-diagnostic period by study design, we 
excluded from the analysis all injuries with a death record identified at the time of hospital 
discharge.  
Table 5.1.2 Injury classification. 
  ICD-10 
 
ICD-9 
  Diagnosis code E-code 
 
Diagnosis code E-code 
Any Injury S00-T98  V01-Y98   800-999  (E)807-(E)999 
Iatrogenic Injury 1. Drug or biological substances; 
2. Medical procedures and care; 
2.1 Hemorrhage or hematoma; 
2.2 Accidental puncture/rapture of wound; 
2.3 Infection; 
2.4 Prosthetic device, implant, and graft; 
2.5 Unspecified and others; 
 Non-Iatrogenic Injury  
1. By nature of injury; 
  
1.1 Fracture 
1.2 Contusion or superficial 
1.3 Open wound 
1.4 Internal organ injury 
1.5 Effect of foreign body entering orifice 
1.6 Dislocation 
1.7 Others 
2. By region of injury; 2.1 Upper extremity  
2.2 Head and neck 
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2.3 Lower extremity 
2.4 Trunk 
2.5 Others 
3. By mechanism of injury; 3.1 Fall 
3.2 Struck by or against 
3.3 Transport 
3.4 Nature,animal,plant 
3.5 Cut or pierce 
3.6 Poisoning 
3.7 Others 
4. By place of occurrence; 4.1 Residential areas 
4.2 Transportation area/Street and highway 
4.3 Sports and athletics area 
4.4 School, other institution and public administrative area 
4.5 Others 
5. By manner of intent; 
 
5.1 Unintentional (accidents) 
5.2 Intentional self-harm 
5.3 Assault 
5.4 Undertermined and others 
5.1.4 Statistical analyses 
We first calculated the incidence rates (IRs) of outcomes, i.e., iatrogenic and non-iatrogenic 
injuries during pre-diagnostic, diagnostic and post-diagnostic periods among all patients, using 
the number of injury events divided by accumulated person-months at risk. The time spent in 
hospital (i.e. days from admission to discharge for each hospitalization), regardless of discharge 
diagnosis, was not counted as time at risk. To perform a within-individual comparison, we used 
conditional Poisson regression to estimate the incidence rate ratios (IRRs) and 95% confidence 
intervals (CIs) for the risks of injuries, by comparing the IRs during the diagnostic and post-
diagnostic periods with the IRs during the pre-diagnostic period, of the same patient (156). 
IRRs were calculated for cancer patients altogether and by cancer subgroups. For all cancer 
patients together, we separately estimated the IRRs for every two-week period during the 
diagnostic and post-diagnostic periods. We additionally estimated the associations for different 
subtypes of iatrogenic injuries and non-iatrogenic injuries.  
5.2 INJURIES IN RELATION TO DIAGNOSTIC WORKUP OF CERVICAL 
CANCER (STUDY II) 
5.2.1 Study design and participants 
We identified in total 3,016,307 women who were born in Sweden during 1912-1990 and were 
18 years and above during 2001-2012. We used uniquely assigned PIN to link all these women 
to the NKCx, Cancer Register, Patient Register, Total Population Register and Cause of Death 
Register. After linkage, all women were individually followed from 1st of January or their 18th 
birthday, until a diagnosis of CIN3 or invasive cervical cancer, a diagnosis of any other cancer, 
a total hysterectomy, emigration, death, or the end of study period (December 31st 2012), 
whichever came first.  
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Figure 5.2.1 The flowchart and design of Study II. 
 
5.2.2 Definitions of diagnostic workup 
The diagnostic procedures of cervical cancer and its precursor lesions during the study period 
commonly include cytology test by Pap smear and histology test by punch biopsy. It usually 
takes 4-6 weeks for the cytological findings to be delivered to a woman after taking a smear. 
The diagnostic workup for women with “normal smear” was defined as a two-month period 
starting from the day when a smear was taken, i.e. the waiting time for a normal smear result. 
The diagnostic workup for women with a diagnosis of invasive cervical cancer and its precursor 
lesions was defined as the time interval between the first smear or punch biopsy (start of 
workup) and surgical treatment if surgically treated or two months after the latest smear or 
biopsy if not treated surgically (end of workup).  
Sometimes women could be managed differently based on screening findings or symptoms, 
and not every woman undergo all diagnostic procedures. For example, women with mild 
cytological lesions can be managed by repeated smears without punch biopsy, and women with 
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symptoms can be directed to take punch biopsy without taking smears. Therefore, we 
categorized women during each diagnostic procedure based on their test results. All women 
included in this study were classified as unexposed group (women with normal smear) or 
exposed group (women with a diagnostic workup of cervical abnormalities). We separately 
studied the time interval between cytology and histology by classifying women according to 
cytological results (LSIL or HSIL), and between histology and treatment by classifying women 
according to histological results (CIN1, CIN2, CIN3/AIS (adenocarcinoma in situ), or invasive 
cancer). To contrast the risk of injuries during diagnostic procedures to therapeutic procedures, 
we further defined a six-month time period after surgical treatment for women treated 
surgically, and defined a six-month time period after end of diagnostic workup for untreated 
women as the post-workup period (Figure 5.2.1). 
5.2.3 Ascertainment of injuries 
The outcomes of interest in this study were hospitalized iatrogenic and non-iatrogenic injuries, 
identified from the Swedish Patient Register. We used the main discharge diagnosis ICD-10 
codes S00-T98, and the external causes E-codes V01-Y98, to identify injuries. Because women 
can be referred to outpatient and overnight inpatient care for temporary discomfort after punch 
biopsy, we therefore included only iatrogenic injuries with at least two days of hospital 
admission as outcomes of interest. Repeated events were taken into account, except for 
consecutive events with the same primary diagnosis or within one week of each other, which 
were considered as the same event.  
5.2.4 Statistical analyses 
We described the characteristics of unexposed and exposed women by histology diagnosis. 
The differences in age, calendar period (2001-2004, 2005-2008 and 2009-2012), screening 
adherence, highest education level, income and cohabitation status between unexposed and 
exposed women were calculated using Pearson’s Chi-square test. We calculated crude IRs 
using numbers of injury events divided by accumulated person-months at risk, discarding days 
spent during hospital admission. We calculated crude IRs of iatrogenic injuries that required at 
least two days of admission and hospitalized non-iatrogenic injuries during the two months 
after a normal smear among unexposed women, and during the diagnostic and post-workup 
period of the exposed women. We further estimated the IRRs and 95% CIs by comparing the 
IRs of the exposed women with the IRs of the unexposed women, using Poisson regression. 
To examine the risk of injuries in relation to specific diagnostic procedures in comparison to 
therapeutic procedures, we calculated IRs and IRRs separately, between cytology and 
histology, between histology and treatment (or end of workup), and during post-workup period. 
All estimates were adjusted for age at smear taking or diagnosis, calendar period, screening 
adherence, education, income and cohabitation status.  
Screening adherence was calculated as the percentage of the actual participation times of 
cervical screening divided by recommended participation times according to the screening 
guideline (157). Registered smears beyond screening age were not counted in this calculation. 
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Because socioeconomic status and cohabitation status were associated with patients’ health 
seeking behaviors (158), we retrieved information from LISA on the highest education level, 
individualized disposable income, and cohabitation status.  
5.3 PSYCHIATRIC DISORDERS AND CARDIOVASCULAR DISEASES DURING 
DIAGNOSTIC WORKUP OF BREAST CANCER (STUDY III) 
5.3.1 Study design and participants 
By linking the Total Population Register to Cancer Register and SHR using PIN, we 
performed a cohort study following all women (N=608,140) residing in Skåne from January 
1st, 2005 or 18th birthday, whichever came later, until December 31st 2014, death, diagnosis 
of breast cancer, diagnosis of any other cancer, total mastectomy, or emigration out of Skåne, 
which occurred first.  
 
Figure 5.3.1 Flowchart and design of Study III, a population-based cohort study during 2005-2014 in Skåne, 
Sweden. 
5.3.2 Definition of a diagnostic workup 
We identified three groups of women as exposed to a diagnostic workup of potential breast 
cancer that were exclusive to each other. 
1) Breast cancer (N=8,512): all women received a first diagnosis of breast cancer during 
study period and identified from the Cancer Register. 
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2) Benign tumor (N=4,435): patients with a benign tumor in breast experience a similar 
diagnostic process as breast cancer patients until receiving a definite diagnosis. Among 
women without a breast cancer diagnosis, we identified all patients with a primary diagnosis 
of benign tumor in breast or breast cancer in situ from the Cancer Register and SHR. We 
referred to this group as “benign tumor”, due to the fact that 98.7% patients in this group had 
a diagnosis of benign tumor.  
3) Lump in breast (N=15,714): unspecified lump in breast is one of the most common 
symptom for breast cancer patients and it is often the reason to start a breast diagnostic 
workup. Among women without a diagnosis of breast cancer or benign tumor in breast or 
breast cancer in situ, we identified women with unspecified lump in breast from SHR.  
We had no information in the register regarding the course of diagnostic workup of potential 
breast cancer. According to the national cancer care program, the median waiting time from a 
well-founded suspicion for a potential breast cancer until start of initial treatment was 42 days 
for 80% of breast cancer patients in Skåne (159). To validate the waiting time before diagnosis 
using data from SHR, we counted number of healthcare visits during each week before 
diagnosis among women with breast cancer, and compared the number of visits per week to 
the week before. As a result, we found that women started to have increased number of 
healthcare visits from the 6th week before diagnosis. Therefore, the start of diagnostic workup 
of potential breast cancer was defined as from the 6 weeks before diagnosis.  
Apart from women that had a breast diagnostic workup, women who did not have a breast 
diagnostic workup during the follow-up were considered as reference (N=579,479). Women 
who underwent a breast diagnostic workup contributed also their person-time to the reference 
group before the start of workup (Figure 5.3.1). 
5.3.3 Ascertainment of psychiatric disorders and cardiovascular diseases 
We used ICD-10 codes I00-I99 to identify all diagnoses of cardiovascular diseases and F10-
F99 for all diagnoses of psychiatric disorders from SHR and considered them as the primary 
outcomes of interest. We included deaths due to cardiovascular diseases from the Cause of 
Death Register that were not preceded by a related hospital visit according to SHR, as 
additional outcomes of cardiovascular diseases. Repeated outcomes were included except for 
subsequent events with the same diagnosis and occurred within one month of each other. We 
further classified psychiatric disorders as stress reaction or adjustment disorder, depression, 
anxiety, substance abuse and others. Cardiovascular diseases were grouped into myocardial 
infarction, hypertensive diseases or aneurysm of the heart, embolism or thrombosis, stroke 
and other diseases of the circulatory system.  
5.3.4 Statistical analyses 
We calculated the crude incidence rates (IRs) of psychiatric disorders and cardiovascular 
diseases for reference group and during the six weeks before diagnosis for all exposed women, 
by dividing the number of outcome events with the accumulated person-months at risk. We 
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used Poisson regression to estimate the IRRs and 95% CIs, by comparing the IRs of the exposed 
women with the IRs of the reference group. Because outcome events were measured 
repeatedly, we used a clustered sandwich estimator to control for the intra-individual 
correlation. The underlying timescale in analysis was attained age. All estimates were 
additionally adjusted for cohabitation status, registered parish as a proxy for socioeconomic 
status (both ascertained from the Total Population Register), and pre-existing psychiatric 
disorder or cardiovascular disease (ascertained from SHR). Status on pre-existing psychiatric 
disorders or cardiovascular diseases was updated at the start of each time period, to account for 
the time-varying nature of these variables.  
Because the association might differ for a breast diagnostic workup initiated due to symptoms 
compared to a workup initiated by screening findings, we conducted the same analysis 
separately for workups due to screening and due to symptoms, during 2009-2014, when such 
information on breast cancer screening was largely available in SHR. 
5.4 NSAID USE AND UNNATURAL DEATHS AFTER CANCER DIAGNOSIS 
(STUDY IV) 
5.4.1 Study design and participants 
Due to the availability of data on dispensed medication since 1 July 2005 in the Sweden 
Prescribed Drug Register, we identified in total 403,322 patients with a newly diagnosed cancer 
between October 2005 and December 2014 from the Swedish Cancer Register. Using the 
uniquely assigned PIN to all residents in Sweden, all patients were cross-linked to different 
registers to obtain personal information on death (from the Swedish Cause of Death Register) 
and emigration (from the Total Population Register). After excluding patients who died 
(N=155) and emigrated (N=14,724) before cancer diagnosis, 388,443 patients were followed 
from the date of cancer diagnosis, until emigration, death, or December 31, 2014, whichever 
came first.  
5.4.2 Definitions of medication periods 
In Sweden, low-dose aspirin cannot be purchased over-the-counter without a prescription, we 
therefore focused on aspirin with a daily dose of 75 or 160 mg. From the Swedish Prescribed 
Drug Register, patients who had medication dispensed with ATC codes B01AC06, B01AC30 
and B01AC56 were considered as medicated with low-dose aspirin, and with ATC codes 
starting with M01A were considered as medicated with non-aspirin NSAIDs.  
We identified all aspirin and non-aspirin NSAIDs dispensed between three months before 
cancer diagnosis and the end of follow up, for each cancer patient. We summed up the multiple 
prescriptions at the same dispense date for the same drug, and detracted any unused drug that 
was returned to the pharmacies from the total amount. To construct the on- and off-medication 
periods for each patient during follow-up, we took advantage of the dispense date and the 
prescription text updated for each prescribed medication. Days on medication can be estimated 
from the prescription text of the dispensed drug. Because the defined daily dose does not 
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necessarily correspond to the recommended or prescribed daily dose, we estimated the time on 
medication as the division of the total amount of dispensed drug by the prescribed daily dosage 
for medication per medicated period, for each patient. The prescribed daily dosage for each 
medicated period was largely extracted from the prescription text. The defined daily dose was 
used only when the prescription text was not available.  
Therefore, the on-medication period was defined as the time interval from the most recent 
dispense date of aspirin or non-aspirin NSAIDs, until the last day when specific NSAID was 
estimated to be consumed. Time periods outside on-medication periods among patients who 
had ever used NSAIDs, and all time periods during follow-up of patients who did not use any 
NSAID, were defined as off-medication periods (Figure 5.4.1).  
Figure 5.4.1. Illustration of on- and off-medication periods during follow-up using one fictitious patient as an 
example* 
 
*Solid line of axis “time in months” is follow-up time. Dot line of axis “time in months” is the time before follow-
up. Patient starts to be at risk from time 0 and onwards. Gray box represents on-medication period, and filled circle 
stands for occurrence of failure or censoring.  
 
5.4.3 Ascertainment of unnatural deaths 
We used the ICD-10 codes X60-X84, V01-X59 and Y85-Y86 to ascertain deaths by suicide or 
accidents. Death due to accident was further classified as death due to transport accident, fall, 
accidental threat to breathing, unspecified fracture, or others.  
Table 5.4.1. Classification of unnatural deaths. 
Unnatural death  ICD-10 
Death due to suicide X60-X84 
Death due to accident V01-X59, Y85-Y86 
- transport accident V01-V99 
- fall W00-W19 
- accidental threats to breathing W65-W84 
- unspecified fracture X590 
- others W20-W64, W85-W99, X00-X58, X599, Y85-Y86 
5.4.4 Statistical analyses 
We used Cox proportional hazards regression model to estimate the hazard ratios (HRs) and 
95% CIs of suicide and death due to accident after cancer diagnosis, by comparing the on-
  29 
medication periods with the off-medication periods of aspirin and non-aspirin NSAIDs. 
Population attributable fraction (PAF) is defined as the fraction of cases in population that 
can be attributable to a specific exposure (160). We estimated PAF to measure the size of 
unmedicated population that was affected due to a lack of exposure (161). We also separately 
assessed the association by major causes of death due to accident. In all regression models, 
we used time since cancer diagnosis as the underlying timescale, and additionally adjusted 
the estimates for age at diagnosis (continuous variable), sex, cancer type, cancer stage 
(localized limited, localized advanced, regional spread, distant metastasis, unknown, or not 
applicable), highest education level, occupation, cohabitation status, pre-existing psychiatric 
disorders, chronic disease score (continuous variable), and calendar year of diagnosis.  
Information on the highest education level, occupation, and cohabitation status was retrieved 
from LISA. We defined pre-existing psychiatric disorders as having any inpatient or 
outpatient hospital visit for psychiatric disorders from 1987 until the date of cancer diagnosis, 
and updated such information for each period (ICD-9 codes 290-319, and ICD-10 codes F10-
F99). Chronic Disease Score was a measure of comorbidity based on the prescribed 
medications dispensed for each patient, after excluding anxiolytics, antidepressants, and 
antipsychotic and anti-inflammatory medications. 
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6 RESULTS 
6.1 INJURIES AROUND CANCER DIAGNOSIS (STUDY I) 
Iatrogenic injuries 
We identified in total 7,306 iatrogenic injuries during the diagnostic period of all cancer 
patients, corresponding to an IR of 0.60 per 1,000 person-months. We found a statistically 
significantly increased rate of iatrogenic injuries among patients with all cancers during both 
diagnostic and post-diagnostic periods. The rate increase was more pronounced during the 
diagnostic period (IRR 7.0; 95% CI, 6.6 to 7.4), than post-diagnostic period (IRR 3.5; 95% CI 
3.3 to 3.8), compared to the pre-diagnostic period. The rate increase was higher during 
diagnostic period than post-diagnostic period for all cancer types. Patients with cancers of the 
central nervous system were at greatest rate increase of iatrogenic injuries, and patients with 
non-melanoma skin cancer had the smallest rate increase, during diagnostic period (Figure 
6.1.1). 
 
Figure 6.1.1 Incidence rates (per 1,000 person-months) and incidence rate ratios of iatrogenic injuries during the 
diagnostic period and post-diagnostic period, compared to the pre-diagnostic period, among 720,901 cancer 
patients diagnosed during 1991-2009 in Sweden*   
** Severe cancers include cancers of esophagus, liver, and pancreas. Smoking-related cancers include cancers 
of mouth, nasopharynx, esophagus, pancreas, lung, kidney, bladder and urinary track. Alcohol-related cancers 
include cancers of mouth, larynx, esophagus, biliary duct and liver.  
 
 
During the diagnostic period, the IRRs of iatrogenic injuries started to increase from two weeks 
before cancer diagnosis and peaked within the first two weeks after cancer diagnosis (IRR 48.6; 
95% CI, 37.3 to 63.5). The magnitude of rate increase was smaller thereafter but remained 
statistically significant during the entire diagnostic period (Figure 6.1.2). In contrast, the rise in 
the rate of iatrogenic injuries was found to be smaller and decreased monotonically throughout 
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the post-diagnostic period (Figure 6.1.2). During the diagnostic period of all cancer patients, 
the greatest rate increase was observed for infection, wound complications, and bleeding. 
(Figure 6.1.3) 
 
Figure 6.1.2 Incidence rate ratios and 95% CI of injuries during the diagnostic period and post-diagnostic period, 
compared to the pre-diagnostic period, among 720,901 cancer patients diagnosed during 1991-2009 in Sweden. 
     
 
Figure 6.1.3 Incidence rate ratios and 95% CI of iatrogenic injuries during the diagnostic period compared to the 
pre-diagnostic period by injury subtypes, among 720,901 cancer patients diagnosed during 1991-2009 in Sweden. 
X-axis was displayed on logarithmic scale of base 10 for better visualization.  
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Non-iatrogenic injuries 
We identified in total 8,331 non-iatrogenic injuries among all cancer patients during the 
diagnostic period, representing an IR of 0.69 per 1,000 person-months. Compared to the pre-
diagnostic period, we found an increased rate of non-iatrogenic injuries throughout the 
diagnostic (IRR, 1.9; 95% CI, 1.8 to 2.0) and post-diagnostic (IRR 2.0; 95% CI 1.9 to 2.1) 
periods (Figure 6.1.4). The rate increase was similar during diagnostic period and post-
diagnostic period for all cancers, with some variations across cancer subgroups. During the 
diagnostic period, the highest rate increase was observed for patients with lymphatic or 
hematopoietic cancers and cancers of central nervous system.  
 
Figure 6.1.4 IRs (per 1,000 person-months) and IRRs of non-iatrogenic injuries during the diagnostic period and 
post-diagnostic period, compared to the pre-diagnostic period, among 720,901 cancer patients diagnosed during 
1991-2009 in Sweden*   
** Severe cancers include cancers of esophagus, liver, and pancreas. Smoking-related cancers include cancers 
of mouth, nasopharynx, esophagus, pancreas, lung, kidney, bladder and urinary track. Alcohol-related cancers 
include cancers of mouth, larynx, esophagus, biliary duct and liver.  
 
 
When focusing on smaller time intervals during diagnostic period, the rate of non-iatrogenic 
injuries was noted to increase largely from four weeks before to two weeks after cancer 
diagnosis, with highest rate increase observed during the two weeks before cancer diagnosis 
(IRR 5.3; 95% CI, 4.6 to 6.1) (Figure 6.1.2). The rate increment was declined after two weeks 
post cancer diagnosis. Similar to iatrogenic injuries, the rate increase during post-diagnostic 
period for non-iatrogenic injuries constantly decreased over time. We observed an increased 
rate of non-iatrogenic injuries during diagnostic period compared to the pre-diagnostic period 
for most injury subtypes, except for injuries occurred in sports and athletics area and assault 
(Figure 6.1.5).  
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Figure 6.1.5 IRRs and 95% CI of non-iatrogenic injuries during the diagnostic period compared to the pre-
diagnostic period by injury subtypes, among 720,901 cancer patients diagnosed during 1991-2009 in Sweden. 
 
When focusing on the most common types of non-iatrogenic injuries by manner of intent, there 
was an increased rate of 
unintentional and intentional 
injuries before and after cancer 
diagnosis (Figure 6.1.6). An 
increased rate of unintentional 
injuries was noted from four weeks 
before to four weeks after cancer 
diagnosis. The increased rate of 
intentional injuries, i.e. self-harm 
behaviors, was observed only 
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during the weeks after cancer diagnosis.  
Figure 6.1.6 IRRs and 95% CI of non-iatrogenic injuries during the diagnostic period compared to the pre-
diagnostic period by unintentional and intentional injury, among 720,901 cancer patients diagnosed during 1991-
2009 in Sweden. 
*Time is divided into every four weeks for unintentional injuries and every eight weeks for intentional injuries, 
due to smaller numbers of the latter. 
 
6.2 INJURIES IN RELATION TO DIAGNOSTIC WORKUP OF CERVICAL 
CANCER (STUDY II) 
There were 1,853,510 women with only normal smear result, representing 95.6% of all 
participants. When characterizing women by histology diagnosis, 22,435 women with CIN1, 
20,692 women with CIN2 and 36,542 women with CIN3/AIS were identified during follow-
up. The number of women with invasive cervical cancer was 5,189 (0.3% of all participants). 
About half of the diagnostic workups of women with invasive cervical cancer started from a 
cytological smear (52.5%). Approximately 76% of the exposed women underwent a surgical 
treatment, including 44% of women with CIN1, 75% of women with CIN2, 80% of women 
with CIN3/AIS, and 49% of women with invasive cancer. Advanced histology diagnosis was 
associated with older age at diagnosis, earlier calendar period, lower screening adherence, 
lower education level, lower income, and non-cohabitation status (Table 6.2.1). 
Table 6.2.1. Characteristics of study participants by histology diagnosis, a nationwide cohort study during 2001-
2012 in Sweden. 
Characteristics Normal 
smear 
CIN1* CIN2* CIN3/AIS* Invasive 
cervical 
cancer 
P value 
No. (%) 1 853 510 
(95.62) 
22 435 
(1.16) 
20 692 
(1.07) 36 542 (1.89) 
5 189 
(0.27) 
 
Workup started from 
cytological smear (%)      
 
Yes 100 99.96 97.81 95.65 52.51  
No - 3.17 2.19 4.35 47.49  
Age, years (%) <.0001 
18-40 53.63 70.35 77.32 76.31 24.11  
41-65 45.74 27.77 21.39 22.17 36.85  
>65 0.63 1.88 1.29 1.52 39.04  
Calendar period (%) <.0001                                       
2001-2004 70.46 29.98 31.32 34.01 36.15  
2005-2008 17.69 29.14 30.35 32.93 32.36  
2009-2012 11.86 40.88 38.33 33.06 31.49  
Screening adherence (%) <.0001                                       
Low 35.11 22.38 21.97 43.02 68.82  
Medium 22.12 18.22 17.47 15.43 10.85  
High 23.10 22.61 22.38 13.57 10.10  
Very high 19.67 36.80 38.18 27.98 10.23  
Education (%)      <.0001                                       
<9 years or unknown 11.62 9.00 9.83 11.10 34.09  
9-12 years 49.13 48.60 50.01 51.46 42.69  
>12 years 39.26 42.40 40.15 37.44 23.22  
Income (%)      <.0001                                       
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Low 27.74 23.51 25.33 28.08 28.70  
Medium 27.80 25.12 25.00 25.57 31.78  
High 26.71 26.51 26.16 24.66 21.60  
Very high 17.75 24.87 23.51 21.70 17.92  
Cohabitation status (%)      <.0001                                       
Not cohabitating 58.55 79.71 81.84 76.01 66.33  
Cohabitating 41.45 20.29 18.16 23.99 33.67  
*CIN = Cervical intraepithelial neoplasia, CIN3/AIS includes carcinoma in situ and adenocarcinoma in situ. 
 
Iatrogenic injuries with more than two days of hospital admission 
There were 13 and 26 iatrogenic injuries identified between cytology and histology, and 
between histology and treatment among all exposed women, respectively (Table 6.2.2). 
Compared to women with normal smear, no statistically significantly increased rate of 
iatrogenic injuries was observed after cytology and before histology among women with LSIL 
and HSIL (IRR,1.93; 95% CI 0.99-3.78; IRR,1.25, 95% CI 0.39-4.07). Women with CIN3/AIS 
and invasive cancer had an increased rate after histology and before treatment (IRR,3.81, 95% 
CI 1.83-7.93 for CIN3/AIS; IRR,15.74, 95% CI 6.42-38.61 for invasive cancer). All women 
exposed to a diagnostic workup had an increased rate of iatrogenic injuries during the post-
workup period, with much greater magnitude of rate increase compared to that of the diagnostic 
workup, especially for women with invasive cancer. Similar results were noted when 
considering only the first iatrogenic injury event per woman. 
Table 6.2.2 Incidence rates (IRs, per 1 000 person-months) and incidence rate ratios (IRRs) of iatrogenic injuries 
during the diagnostic workup of women with cervical cancer and its precursor lesions, compared to women 
with normal smear, a nationwide cohort study during 2001-2012 in Sweden 
 No. of women No. of events  Crude IRs  IRR (95% CI) 
Iatrogenic injuries that required ≥2 days of hospital admission 
  Normal smear† 1 853 510 103 0.03 1.0 
Between cytology and histology‡ 
  LSIL 44 519 10 0.05 1.93 (0.99-3.78) 
  HSIL 31 591 3 0.04 1.25 (0.39-4.07) 
Between histology and treatment‡ 
  CIN1 22 435 5 0.04 1.51 (0.59-3.87) 
  CIN2 20 692 4 0.04 1.73 (0.62-4.81) 
  CIN3/AIS§ 36 542 9 0.11 3.81 (1.83-7.93) 
  Invasive cancer 5 189 8 1.07 15.74 (6.42-38.61) 
Post-workup period ‡ 
  CIN1 22 435 16 0.13 4.55 (2.58-8.03) 
  CIN2 20 692 24 0.21 7.41 (4.62-11.88) 
  CIN3/AIS§ 36 542 88 0.42 13.50 (9.94-18.33) 
  Invasive cancer 5 189 44 2.07 41.01 (24.80-67.83) 
† Normal smear: a 2-month period starting from the day of smear for women with normal smear. 
‡ Between cytology and histology: between the first cytology and the first histology among women with both 
cytology and histology in the diagnostic workup. Between histology and treatment: between the first histology 
and treatment for women that were treated surgically and between the first histology and two months after for 
women that were not treated surgically (including women without cytology). Post-workup period was defined as 
a 6-month period after diagnostic workup. 
§ CIN3/AIS includes in situ and adenocarcinoma in situ. 
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Non-Iatrogenic injuries  
We identified, in total, 37 and 51 non-iatrogenic injuries between cytology and histology, and 
between histology and treatment among all exposed women, respectively (Table 6.2.3). 
Compared to women with normal smear, we did not observe a statistically significant increased 
rate of non-iatrogenic injuries between cytology and histology among women with LSIL and 
HSIL (IRR,0.86, 95% CI 0.56-1.33; IRR,1.35, 95% CI 0.80-2.28). Between histology and 
treatment, there was an increased rate among women with invasive cervical cancer (IRR,3.86, 
95% CI 1.99-7.51) but not for women with CIN1, CIN2, or CIN3/AIS. Among women with 
invasive cancer, the rate increase of non-iatrogenic injuries during diagnostic workup was 
compariable to the post-workup period after treatment (Table 6.2.3). Similar results were noted 
when only accounting the first injury event per woman. 
Table 6.2.3 Incidence rates (IRs, per 1 000 person-months) and incidence rate ratios (IRRs) of non-iatrogenic 
injuries during the diagnostic workup of women with cervical cancer and its precursor lesions, compared to 
women with normal smear, a nationwide cohort study during 2001-2012 in Sweden* 
 No. of women No. of events  Crude IRs  IRR (95% CI) 
Non-iatrogenic injuries that required at least one day of hospital admission 
  Normal smear† 1 853 510 460 0.12 1.0 
Between cytology and histology‡ 
  LSIL 44 519 22 0.12 0.86 (0.56-1.33) 
  HSIL 31 591 15 0.20 1.35 (0.80-2.28) 
Between histology and treatment‡ 
  CIN1 22 435 18 0.14 0.97 (0.52-1.84) 
  CIN2 20 692 11 0.12 0.88 (0.48-1.60) 
  CIN3/AIS§ 36 542 13 0.16 1.08 (0.59-1.95) 
  Invasive cancer 5 189 9 1.20 3.86 (1.99-7.51) 
Post-workup period ‡ 
  CIN1 22 435 18 0.15 1.07 (0.66-1.74) 
  CIN2 20 692 15 0.13 0.97 (0.55-1.71) 
  CIN3/AIS§ 36 542 28 0.13 0.89 (0.60-1.33) 
  Invasive cancer 5 189 24 1.13 3.80 (2.45-5.90) 
† Normal smear: a 2-month period starting from the day of smear for women with normal smear. 
‡ Between cytology and histology: between the first cytology and the first histology among women with both 
cytology and histology in the diagnostic workup. Between histology and treatment: between the first histology 
and treatment for women that were treated surgically and between the first histology and two months after for 
women that were not treated surgically (including women without cytology). Post-workup period was defined as 
a 6-month period after diagnostic workup. 
§ CIN3/AIS includes in situ and adenocarcinoma in situ. 
 
6.3 PSYCHIATRIC DISORDERS AND CARDIOVASCULAR DISEASES DURING 
DIAGNOSTIC WORKUP OF BREAST CANCER (STUDY III) 
During the study period, 15, 714 women with lump in breast were diagnosed, with a mean age 
of 41 years. The age at diagnosis for 4,435 women with benign tumor and 8,512 women with 
breast cancer were 45 and 63 years. Among women with breast cancer, 90% were treated 
surgically. The proportion of women receiving surgical treatment were 30% for patients with 
benign tumor and less than 2% for patients with unspecified lump in breast. The proportion of 
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women with breast cancer that had pre-existing cardiovascular diseases was 37%, while the 
proportion was 19% for women with either lump in breast or benign tumor.  
Psychiatric disorders 
During the six weeks before diagnosis, we identified 521 women with unspecified lump in 
breast, 145 women with benign tumor, and 253 women with breast cancer that had psychiatric 
disorders, corresponding to 3.3%, 3.3%, and 3.0% of all women with lump, benign tumor and 
breast cancer, respectively.  
There was an increased rate of psychiatric disorders among all women exposed to a breast 
diagnostic workup, compared to the reference group (IR, 25.5 per 1,000 person-months; IRR, 
1.2; 95% CI, 1.1-1.3). We found a marginally increased rate among women with unspecified 
lump in breast (IRR, 1.1; 95% CI, 1.0 to 1.2), and a statistically significantly increased rate 
among women with benign tumor (IRR, 1.3; 95% CI, 1.1 to 1.5) and breast cancer (IRR, 1.4; 
95% CI, 1.2 to 1.6) (Figure 6.3.1). The rate increase was greater for breast cancer patients with 
advanced stage, compared to those with a lower stage. A rate increase was noted for anxiety 
before diagnosis of unspecified lump in breast, for stress reaction or adjustment disorder and 
substance abuse before diagnosis of benign tumor and for all individual psychiatric disorders 
before diagnosis of breast cancer. Similar rate increase of psychiatric disorders was noted 
during the six weeks before diagnosis for women that had a breast diagnostic workup due to 
symptoms, but not due to screening (Figure 6.3.2). 
                         
Figure 6.3.1. IRs (per 1000 person-months) and IRRs of psychiatric disorders during the six weeks before 
diagnosis of women that underwent a breast diagnostic workup, a population-based cohort study during 2005-
2014 in Skåne, Sweden. 
*Reference group included person-time accumulated from women who did not have any breast diagnostic workup 
during the follow-up and the person-time accumulated before the start of workup from women with a breast 
diagnostic workup during the follow-up. 
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Figure 6.3.2. IRs (per 1000 person-months) and IRRs of psychiatric disorders during the six weeks before 
diagnosis, among women that had a breast diagnostic workup during 2009-2014 in Skåne, Sweden, analysis 
according to reason for diagnostic workup. 
*Reference group included person-time accumulated from women who did not have any breast diagnostic workup 
during the follow-up and the person-time accumulated before the start of workup from women with a breast 
diagnostic workup during the follow-up. 
 
Cardiovascular diseases 
During the six weeks before diagnosis, 1.8% (N=284) of women with unspecific lump in 
breast, 2.5% (N=110) of women with benign tumor, and 8.3% (N=708) of women with breast 
cancer had a diagnosis of cardiovascular diseases. Among all exposed women, there was an 
increased rate of cardiovascular diseases during the six weeks before diagnosis (IR, 30.0 per 
1000 person-months; IRR, 1.5; 95% CI, 1.5 to 1.6). The rate increased was observed mainly 
among women with benign tumor (IRR, 1.3; 95% CI, 1.1 to 1.6) and breast cancer (IRR, 1.9; 
95% CI, 1.8 to 2.0). The rate increase was minimal among women with unspecified lump in 
breast (IRR, 1.1; 95% CI, 1.0 to 1.2) (Figure 6.3.3). The rate increase was greater for advanced 
breast cancer compared to a lower stage cancer.  
                
Figure 6.3.3. IRs (per 1000 person-months) and IRRs of cardiovascular diseases during the six weeks before 
diagnosis of women that underwent a breast diagnostic workup, a population-based cohort study during 2005-
2014 in Skåne, Sweden. 
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*Reference group included person-time accumulated from women who did not have any breast diagnostic workup 
during the follow-up and the person-time accumulated before the start of workup from women with a breast 
diagnostic workup during the follow-up. 
 
There was an increased rate for other diseases of the circulation system before the diagnosis of 
unspecified lump in breast, and for hypertensive diseases or aneurysm of the heart before the 
diagnosis of benign tumor. We found a higher rate for most types of cardiovascular diseases 
before the diagnosis of breast cancer. We found a rate increase of cardiovascular diseases 
during the six weeks before diagnosis for women that had a breast diagnostic workup due to 
screening and women that had a diagnostic workup due to symptoms (Figure 6.3.4).  
           
Figure 6.3.4 IRs (per 1000 person-months) and IRRs of cardiovascular diseases during the six weeks before 
diagnosis, among women that had a breast diagnostic workup during 2009-2014 in Skåne, Sweden, analysis 
according to reason for diagnostic workup. 
*Reference group included person-time accumulated from women who did not have any breast diagnostic workup 
during the follow-up and the person-time accumulated before the start of workup from women with a breast 
diagnostic workup during the follow-up. 
 
6.4 NSAID USE AND UNNATURAL DEATHS AFTER CANCER DIAGNOSIS 
(STUDY IV) 
Among all cancer patients, 29.7% of the cancer patients used aspirin (N=115,320) and 29.1% 
used non-aspirin NSAIDs (N=112,994) during follow-up. The mean age at diagnosis was 74 
years for patients with aspirin use, and 65 years for patients without aspirin use. The mean age 
was 64 years for patients with use of non-aspirin NSAIDs, and 69 years for patients without 
use of non-aspirin NSAIDs. Compared to patients without aspirin use, patients with aspirin use 
were more likely to be male, older at cancer diagnosis, less educated, unemployed or retired, 
and had higher chronic disease score. Patients with non-aspirin NSAID use were younger, more 
educated, more likely to be cohabitating, and have lower chronic disease score, compared to 
patients without use of non-aspirin NSAIDs.  
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Completed suicide 
There were 287 completed suicides observed during follow-up, among which, 59 were during 
the on-medication period of aspirin and 13 were during the on-medication period of non-aspirin 
NSAIDs (Table 6.4.1). We did not observe a statistically significant association between use 
of aspirin (HR 0.96, 95% CI 0.66-1.39) or non-aspirin NSAIDs (HR 0.95, 95% CI 0.42-2.18) 
and the risk of completed suicide after cancer diagnosis.  
Table 6.4.1. Association of NSAID use with risk of death due to suicide or accident after cancer diagnosis; a 
cohort study of 388,443 cancer patients diagnosed between Oct 2005 and Dec 2014 in Sweden 
Characteristics  Completed suicide Death due to accident 
 N HR (95% CI)* N HR (95% CI)* 
Low-dose aspirin use     
Off medication (Ref)¶ 228 1.0 1 627 1.0 
On medication 59 0.96 (0.66-1.39) 651 0.78 (0.70-0.87) 
     
Use of non-aspirin NSAIDs     
Off medication (Ref)¶ 274 1.0 2 219 1.0 
On medication 13 0.95 (0.42-2.18) 59 0.92 (0.68-1.26) 
*HR, hazard ratio; CI, confidence interval; analyses were adjusted for sex, age at diagnosis, cancer grade, cancer 
type, highest education level, occupation, cohabitation status, history of psychiatric disorders, chronic disease 
score, and calendar year of cancer diagnosis; time since cancer diagnosis was used as the underlying timescale. 
¶Off medication time included follow-up time accumulated among patients without any dispensed NSAIDs 
during follow-up, as well as the non-medicated periods from patients that had any dispensed NSAIDs. 
 
Death due to accident 
There were in total 2,278 deaths due to accident during follow-up, among which, 651 were 
during on-medication period of aspirin and 59 were during the on-medication period of non-
aspirin NSAIDs (Table 6.4.1). Aspirin use was associated with a 22% lower risk of death due 
to accident (HR, 0.78; 95% CI, 0.70-0.87). No association was however noted for non-aspirin 
NSAIDs (HR, 0.92; 95% CI, 0.68-1.26). The PAF analysis suggested that 16% (9-22%) of the 
deaths due to accident could have been avoided if patients had used aspirin during off-
medication period. We found that the reduction in the risks of different types of accidents were 
similar, when separately estimating the association between aspirin use and different types of 
death due to accident (Figure 6.4.1).  
              
Figure 6.4.1. Association of aspirin use with the risk of death due to different types of accidents, a cohort 
study of 388,443 cancer patients diagnosed between Oct 2005 and Dec 2014 in Sweden 
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The risk reduction was more prominent among patients who were men, with a cancer diagnosed 
at early age (<60), with hematopoietic malignancies, without a history of psychiatric disorders, 
or with higher chronic disease score (Figure 6.4.2). 
 
Figure 6.4.2. Association of NSAID use with risk of death due to accident after cancer diagnosis by patient 
characteristics; a cohort study of 388,443 cancer patients diagnosed between Oct 2005 and Dec 2014 in Sweden 
*HR, hazard ratio; CI, confidence interval; analyses were adjusted for sex, age at diagnosis, cancer grade, cancer 
type, highest education level, occupation, cohabitation status, history of psychiatric disorder, chronic disease score, 
and calendar year of cancer diagnosis; time since cancer diagnosis was used as the underlying timescale. 
¶Off medication time included follow-up time accumulated among patients without any dispensed NSAIDs during 
follow-up, as well as the non-medicated periods from patients that had any dispensed NSAIDs. 
£Defined by European Network of Cancer Registries Condensed TNM Scheme and International Federation of 
Gynecology and Obstetrics staging system: localized limited (T-localized/N0/M0 or FIGO 0-I), localized 
advanced (T-advanced/N0/M0 or FIGO II), regional spread (any T/N+/M0 or FIGO III), distant metastasis (any 
T/any N/M+ or FIGO IV), or unknown stage. Hematological malignancies were classified as not applicable. 
**Severe cancer included cancers of esophagus, liver and pancreas. 
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7 DISCUSSION 
7.1 FINDINGS AND IMPLICATIONS 
7.1.1 Stress-related health outcomes during cancer diagnostic workup (Study 
I, II, III) 
Injury is one of the leading causes of non-cancer deaths among cancer patients (1). Existing 
studies have mostly focused on the risk of fatal outcomes, after cancer diagnosis or treatment, 
or during the later phase of cancer survivorship. Little is however known about the risks of 
non-fatal severe injuries during the diagnostic process of cancer. Study I represents the first 
systematic investigation of non-fatal iatrogenic and non-iatrogenic injuries immediately before 
and after a cancer diagnosis. We found that cancer patients had an increased rate of iatrogenic 
injuries starting from two weeks before diagnosis, and an increased rate of non-iatrogenic 
injuries from four weeks before diagnosis. The rise in the rate decreased over time during the 
period after diagnosis, after a peak around diagnosis. In contrast to a smaller and decreasing 
risk in magnitude over time during post-diagnostic period, these findings demonstrate therefore 
a significant impact of cancer diagnostic process and subsequent treatment on risk of 
hospitalized injuries. 
Non-iatrogenic injuries 
An increased risk of self-injury and accidental death during the first year after cancer diagnosis 
has been reported among cancer patients in Sweden (22), the United States (54), and Japan 
(47). In our study, we further noted that the rate of hospitalized non-iatrogenic injuries started 
to increase already from four weeks before cancer diagnosis. This finding is consistent with 
previous studies demonstrating a high level of psychological distress when patients were 
awaiting for a cancer diagnosis (21,28). The rate increase during diagnostic period was noted 
for both intentional and unintentional injuries, with unintentional injuries to be a more common 
outcome. It is important to note that the increased rate of unintentional injuries was observed 
both before and after cancer diagnosis, whereas only after cancer diagnosis for intentional 
injuries. This is in line with previous findings showing a significant risk increase of suicide 
immediately after receiving a cancer diagnosis (22,40,49). These results may indicate different 
mechanisms underlying the rate increase of these injuries before and after diagnosis. In addition 
to symptoms of a progressing disease, the increased rate of non-iatrogenic injuries before 
cancer diagnosis, mainly unintentional injuries, might be attributed to the cognitive impact of 
an upcoming cancer diagnosis, including impaired attention and concentration. Besides the 
cognitive impact, stress-related psychiatric symptoms, such as depression and suicidal ideation, 
might as well contribute to the rate increase after diagnosis.  
The rate increase of non-iatrogenic injuries was observed among all cancers and the magnitude 
varied across cancer types, with the smallest rate increase noted among patients with non-
melanoma skin cancer, a cancer type with relatively mild symptoms and benign prognosis. 
Older patients, patients with non-cohabitation status, and patients with lower socioeconomic 
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status and education level were at higher rate of non-iatrogenic injuries, indicating that these 
groups of patients were more vulnerable to such health outcomes when facing a stressful life 
event. Incidence rate of non-iatrogenic injuries was higher among patients with pre-existing 
psychiatric disorders or previous history of injury, while greater relative risk was noted among 
patients without such histories.  
It has been noted that the social stigma related to cervical cancer might further contribute to a 
high level of psychological distress (79). Women receiving an abnormal test result when 
evaluated for cervical cancer had indeed been reported to have increased risk of anxiety, 
distress, sleep disturbance, and poor concentration (80–82,162,163). In Study II, we found an 
increased rate of non-iatrogenic injuries during the diagnostic workup and the post-workup 
period of women with cervical cancer, although the number of injuries was small during both 
time periods. During the diagnostic workup, the rate increase was noted after biopsy, i.e. when 
waiting for a diagnosis. We did not find a clear rate increase of non-iatrogenic injuries among 
women with cervical precursor lesions. This might be explained by a lower degree of 
psychological distress in relation to receiving a benign diagnosis with a higher possibility to be 
cured (76). We need to note that the inpatient care of non-iatrogenic injuries was very rare 
during the diagnostic workup of cervical cancer and precursor lesions, denoting a minimal 
public health impact from such health outcome.  
Psychiatric disorders and cardiovascular diseases 
High level of psychological distress and its resultant health outcomes, including psychiatric 
disorders, are increasingly recognized among breast cancer patients (33,164). Patients with 
breast cancer and breast cancer in situ were shown to have an increased risk of depression, 
anxiety and stress-related disorders after diagnosis (109). Previous studies have also found that 
women with breast cancer were more likely to die from cardiovascular events (114), both 
during the immediate time period after receiving a cancer diagnosis (22) and after treatment 
(165,166). Evidence is however limited on the risk of cardiovascular and psychiatric 
comorbidities before receiving a breast cancer diagnosis, where the psychological distress 
might be equally, if not more, significant (23). In Study III, we conducted an assessment of the 
risk of psychiatric disorders and cardiovascular diseases during the time period immediately 
before diagnosis and found an increased rate of clinically diagnosed psychiatric disorders and 
cardiovascular diseases. The rate increase was noted for women diagnosed with benign tumor 
in breast and breast cancer. The rate increase was minimal among women diagnosed with 
unspecified lump in breast. The results from self-comparison design confirmed the findings 
after adjusting for shared and unmeasured risk factors that were consistent over time. This 
finding demonstrates that the psychological stress in relation to being evaluated for a potential 
breast cancer is experienced not only by women with malignant and fatal diseases, i.e. cancer, 
but also by women with benign tumor. The rate increase was however not noted among women 
with unspecified lump in breast. In addition to psychological stress, the result pattern might 
also be explained by the role of tumor-related inflammation on the development of stress-
related disorders (167,168). Women with a diagnostic workup of breast cancer due to 
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symptoms had a higher rate of both outcomes, compared to women with a workup due to 
screening. This finding might reflect the impact of disease characteristics. Cancer patients with 
symptoms at the time of diagnosis often have more advanced tumor stage compared to cancer 
patients that are detected upon screening (169). The psychological impact from breast cancer 
screening has since long been discussed and often suggested to be minimal or neglectable as 
compared to the screening benefits (104,108,111,170). Our findings suggests that the adverse 
health impact from cancer evaluation has likely been underestimated in previous studies using 
cancer screening programs alone, where patients with symptoms are often not included 
(170,171). We found a similar rate increase of psychiatric disorders and cardiovascular diseases 
during the weeks before diagnosis, compared to the rate increase between diagnosis and 
treatment (mostly surgery for cancer patients). This indicates a sustained and comparable high 
level of psychological stress when waiting for a cancer diagnosis and when waiting for a cancer 
treatment.  
Psychiatric disorders and cardiovascular diseases might both represent a high level of perceived 
psychological stress in relation to breast cancer diagnostic workup. We combined both 
outcomes as one outcome, defined as having a diagnosis of either a psychiatric disorder or a 
cardiovascular disease. The results are largely similar to that when analysing these two 
outcomes separately. Patients with both outcomes during this critical time window might 
represent a particularly high-risk group. However, the proportion of women with both 
outcomes during the weeks before diagnosis was very small, including less than 1% of women 
among each group. We were therefore unable to further investigate these women.  
7.1.2 Role of NSAID use on severe stress-related health outcomes after 
cancer diagnosis (Study IV) 
Despite of evidence showing an increased risk of death due to accidents and suicide among 
cancer patients (22,47,54,172), the underlying reasons of such risk increase are not clearly 
understood. Inflammation can be a possible pathway between psychological stress related to 
receiving a cancer diagnosis and treatment, and its subsequent health outcomes. In Study IV, 
we assessed the potential effect of anti-inflammatory drug use in modulating the risk of severe 
stress-related health outcomes, using death due to suicide or accidents as examples. To the best 
of our knowledge, Study IV is the first study to investigate the effect of anti-inflammatory drug 
use on the risk of unnatural deaths among patients with a cancer diagnosis. We found that the 
use of low-dose aspirin was associated with a lower risk of unnatural death. We however did 
not observe an association between use of non-aspirin NSAIDs and unnatural death. 
Aspirin is clinically used for prevention and treatment of cardiovascular and thromboembolic 
events (173). Aspirin has also been investigated for its potential use in reducing cancer-specific 
outcomes (139,174,175). Recently, aspirin use has been suggested to reduce the risk of stress-
related health outcomes due to its anti-inflammatory properties (135,176). It is plausible that 
inflammation can drive changes in dopaminergic corticostriatal circuitry, which is correlated 
with deficits in motor function among distressed patients (131). The finding of reduced risk of 
death due to accidents might be explained by the anti-inflammatory properties of aspirin that 
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intervene in this process. This finding is also consistent with evidence from previous studies. 
Cognitive impairment and psychiatric disorders are known risk factors for suicide and injuries 
(177–180). Low-dose aspirin was found to prevent cognitive impairment in an animal model 
of breast cancer (181). In humans, cognitive impairment was associated with an increased risk 
of external injuries (132,133). Further, aspirin was shown to be associated with a decreased 
risk of depression and depressive symptoms and considered as a potential treatment for 
psychiatric disorders (134,135). 
Although reduced risk of death due to accidents was clearly noted, we did not find a clear 
association between use of low-dose aspirin and risk of death due to suicide. It is possible that 
there was indeed no association between aspirin use and risk of suicide. It is also possible that 
a real association is concealed by the lack of statistical power due to very small number of 
suicide cases. When combining suicide and death due to accidents as one outcome (unnatural 
deaths), we found that use of low-dose aspirin was associated with a lower risk of unnatural 
deaths. Unlike death due to accidents, which is mostly unpredictable, completed suicide is 
intentional. During the immediate time period before suicide, patients might stop taking or 
dispensing medications due to a loss of interest in daily activities (182), leading to a distorted 
association.  
Non-aspirin NSAIDs are commonly used as analgesics for arthritic pain, with analgesic, anti-
inflammatory, and anti-pyretic therapeutic properties (183). This class of drugs is used in low 
dose and for short-term due to its side effect on gastrointestinal and cardiovascular systems 
(184–186). In our study, we did not observe an association between use of non-aspirin NSAIDs 
and the risk of death due to accidents or suicide. The contrasting results between use of low-
dose aspirin and non-aspirin NSAIDs are not surprising. In a previous study, low-dose aspirin 
was found to be associated with a decreased risk of depression whereas non-aspirin NSAIDs 
were associated with an increased risk of depression (138). The possibility of chance finding 
cannot be excluded completely because of the relatively smaller number of outcomes noted 
during the on-medication period for other NSAIDs compared to aspirin. 
7.1.3 Other health outcome – Iatrogenic injuries (Study I, II) 
Although an increased mortality due to iatrogenic injuries was recognized for patients with 
colorectal cancer, prostate cancer, and breast cancer (114,187–189), data on burden of 
iatrogenic injuries among cancer patients is generally scarce. The increased risk of iatrogenic 
injuries during cancer diagnostic period, especially immediately after cancer diagnosis, is 
expected. Cancer patients undergo often invasive diagnostic procedures and treatments, and 
are as a result more likely to experience medical complications.  
The burden of iatrogenic injuries is likely associated with the extensiveness of cancer treatment 
strategies (190). We found that patients with non-melanoma skin cancer had the lowest rate 
increase while patients with cancers of central nervous system and colorectal cancer had the 
greatest rate increase, of iatrogenic injuries. Patients with younger age, cohabitation status and 
higher socioeconomic status and education level had a higher increase in the rate of iatrogenic 
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injuries, reflecting the possible more aggressive treatments received by these groups. This is 
consistent with previous finding showing a declining use of definite cancer therapy among 
those with increasing age for cancer patients, independent of comorbidities (191). Patients with 
pre-existing psychiatric disorders or previous history of injury had a higher incidence rates, 
while patient without such histories had a higher relative risk, of iatrogenic injuries. Infection 
and bleeding were the most commonly identified iatrogenic injuries, compared to other 
subtypes. 
Cervical cancer with a worse prognosis is often identified in women who abstain from cervical 
screening (192). One reason for women not participating in screening is the concern of safety 
in screening procedures (86), for instance, bleeding after punch biopsy (193). Although 
overnight watching for temporary discomfort might be expected after diagnostic procedures, 
to be hospitalized for a longer period of time is uncommon. Indeed, in our Study II, the number 
of iatrogenic injuries that required more than two days of inpatient care is very small during 
the diagnostic workup of women with cervical cancer and its precursor lesions. Compared to 
normal smear, we observed an increased rate of iatrogenic injuries during the diagnostic 
workup of cervical abnormalities, and such rate increase was greater after biopsy than after 
smear. This is expected because punch biopsy might cause bleeding and subsequently increase 
the risk of infection (86). Indeed, hemorrhage or hematoma and infections are the most 
common subtypes of iatrogenic injuries during the diagnostic workup of women with invasive 
cancer. We found a higher rate increase among women with invasive cancer than those with 
precursor lesions. Women with invasive cancer have commonly greater vascularity in tumor 
growth (194). Invasive cervical cancer is commonly diagnosed among women with older age 
and lower compliance to cervical cancer screening (76,192,195), which are both risk factors 
for surgery-related adverse events (62,63). The rise in the rate of iatrogenic injuries was smaller 
during the diagnostic workup compared to post-workup period. This finding indicates that the 
impact in relation to the diagnostic procedures is smaller than that of surgical treatment of 
cervical cancer and its precursors (196,197). It is however important to note that the inpatient 
care for two nights or more for iatrogenic injuries in relation to diagnostic workup of cervical 
abnormalities, either invasive cancer or its precursors, is extremely rare.  
7.1.4 Significance 
Our findings of increased rate of non-iatrogenic injuries from Study I call for prevention of 
self-harm and accidental injuries during the time of cancer diagnosis and primary treatment. 
Different prevention strategies should be designed to target different time periods and groups 
at high risk. In Study II, inpatient care of one night or longer for non-iatrogenic injuries was 
very rare during the diagnostic workup of invasive cervical cancer and precursor lesions, 
demonstrating the minimal public health impact during this time period for the cervical cancer 
screening population. There was however an increased risk of non-iatrogenic injuries during 
the diagnostic workup of women with invasive cervical cancer. Findings from Study I and II 
provide novel evidence for the magnitude of rise in the risk of stress-related injuries among 
patients with cancer in general as well as women with invasive cervical cancer. Although these 
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studies focused on injuries that require inpatient care, the findings of increased risk of such 
injuries before and after cancer diagnosis might also apply to milder injuries.  
In Study III, the findings of increased rate of psychiatric disorders and cardiovascular diseases 
during weeks before diagnosis of breast cancer and benign breast tumor call for a better clinical 
surveillance of these two outcomes for women being evaluated for a potential breast cancer, 
regardless of the final diagnosis. The findings of higher rate increase of such outcomes during 
diagnostic workups due to symptoms compared to workups due to screening indicate that using 
screening population alone is not enough to comprehensively estimate the health impact of 
clinical breast cancer evaluation. The population exposed to a cancer diagnostic workup and 
its resultant adverse health impact is much larger than the population that eventually received 
a cancer diagnosis. In study III, only 30% of women received a diagnosis of breast cancer 
among all women who underwent a diagnostic workup of potential breast cancer.  
Different prevention strategies should be designed to target different time periods before and 
after cancer diagnosis and in accordance to different procedures. High-risk groups as well as 
subtypes of stress-related health outcomes should be taken into account by the clinicians and 
policy makers to develop prevention strategies. For instance, patients who are in advanced age 
group, with advanced tumor stage, and without cohabitation status might be the potential high-
risk groups. Specific outcomes including unintentional injuries (such as unspecified fall), stress 
reaction or adjustment disorder, depression and anxiety, and embolism or thrombosis are 
common outcomes, whereas intentional injuries such as suicidal behaviors are extreme 
outcomes. Both outcomes need to be specifically addressed. 
Experiencing these health outcomes during the diagnostic workup may serve as a good proxy 
for vulnerabilities of potential cancer patients in coping with the evaluation process, including 
the diagnostic procedures, discomfort experience, potential side effects, perception of results, 
as well as subsequent treatment if needed. Such vulnerabilities may include a sub-optimal stress 
coping strategy, less resilient personality, lack of proper social support, lower socioeconomic 
standing, and risky behaviors. As a result, patients that already suffer from the diagnostic 
workup may also on average encounter more health problems later on. Knowledge obtained in 
these studies may add valuable evidence in guiding the healthcare system, the families and the 
society, in providing proper support to cancer patients already from the diagnostic workup of 
cancer. Improvement in management of cancer care, such as optimal waiting time and active 
surveillance during the diagnostic workup process might be implemented as a result.  
The use of low-dose aspririn was found to be assocaited with a lower risk of unnatural death. 
This findings from Study IV provide valuable evidence for a potential effective approach to 
reduce the risk of severe stress-related health outcomes following a cancer diagnosis. Given 
the widely use of low-dose aspirin, the repurposing utility with the same dosage guarantees 
that the management of such treatment is safe and with low cost. Because it is often suggested 
to stop taking aspirin prior to major surgery in clinical practice, the results may also call for 
more studies in assessing the importance of aspirin reuptake after surgical treatment.  
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In addition to stress-related health outcomes, our findings also shed light on the burden of 
iatrogenic injuries around cancer diagnosis and call for attention to reduce such burden. 
Although it is hard to evaluate harms from benefits during intensive medical procedures of 
cancer care, the findings from Study I do provide evidence for a critical time window during 
the cancer evaluation and treatment process, in terms of potential prevention of iatrogenic 
injuries in cancer care. Study II adds evidence to the ongoing discussion about potential harms 
of cervical screening procedures. The occurrence of severe iatrogenic injuries during the 
cervical diagnostic procedures is extremely rare, showing the minimal health impact from such 
injuries to the screening population. Nevertheless, iatrogenic injuries still remain as public 
health concern for cancer patients at large. More attention is needed to better understand the 
burden and impact of such health outcomes in cancer care.  
7.2 METHODOLOGICAL CONSIDERATIONS 
Observational studies provide unique opportunity to search for evidence, in contrast to 
experimental studies, due to its longer time of follow-up, heterogeneous population, and real-
world setting (198). Cohort study is the main study design used in this thesis. It represents a 
type of studies that follows a defined group of participants longitudinally to measure outcomes 
over time, under the impact of exposure of interest. Cohort study is considered to provide high 
rank of evidence in the pyramid of observational studies (199). It is feasible and effective to 
perform cohort study to assess common outcomes in favor of the prospectively collected 
information over a long period of time in well-established registers.  
7.2.1 The comparison group 
The comparison group, or reference group, is selected from those who are not exposed. Ideally, 
it is a group of people that is exactly the same as, or as similar as possible to, the exposed group 
except for exposure status, with respect to factors that could influence the studied association. 
Commonly, the comparison is performed between separate groups of individuals, known as 
between-individual comparison. Sometimes study participants can also be compared to 
themselves between different time periods, known as within-individual comparison. 
In our studies, we used within-individual comparison, solely or in compensation to, between-
individual comparison (in Study I and III). We compared each participant during different time 
periods of his or her self, to control for potential influence of shared or unmeasured confounders 
that remained fixed over time, such as genetic and environmental effects. Age impact is 
however not possible to control for by this design. In a within-individual comparison, all 
participants are included in the calculation of absolute risk while only those with different 
outcome status across comparison periods are included in the calculation of relative risk. This 
design has higher efficiency than using the entire cohort, with the consideration of decreasing 
sample size used for analysis of rare outcomes. Because it proxies a self-controlled case-series 
design, there are assumptions to rely on when applying this method (200). Firstly, outcomes 
should be independent recurrent events, or rare non-recurrent events. In Study I and III, 
recurrent outcomes within one week/one month of each other or with the same diagnostic codes 
 50 
were not included in the outcome calculation. We also conducted a sensitivity analysis to only 
include the first outcome event during each time period, and the results confirmed largely the 
main findings. Secondly, when individuals experience multiple exposure periods, the 
occurrence of an event should not alter the probability of subsequent exposure (200). A 
common practice to avoid such bias is to exclude the pre-exposure time period leading to the 
subsequent exposure period from the reference period. In Study I, the design of this study 
automatically corrected for this possible bias by not using the time period immediately before 
the exposure period as the reference. In Study III, it might be possible that patients with 
frequent contact to healthcare system were more likely be detected with a cancer. However, 
the results obtained from this design were consistent with the main findings using a different 
design, largely alleviating the concern. Thirdly, the occurrence of event should not alter the 
observation period (200). The violation of this assumption can happen if an event of interest 
increases the death rate. In Study I, because fatal outcomes were not possible during pre-
diagnostic period by design, we excluded patients that had fatal injuries during diagnostic 
period. Patients who could not survive until the start of post-diagnostic period did not contribute 
to the comparison between post-diagnostic period and pre-diagnostic period. In Study III, death 
during reference period that preceded exposure period was not possible by design. Previous 
studies have been carried out and showed the impact of such bias to be negligible (201,202). 
7.2.2 Survival analysis and models 
Survival analysis was conducted to measure time-to-event outcomes. The use of statistical 
analysis is affected by choice of study design. In cohort study, Poisson and Cox regression 
models can both estimate the relative risk in relation to the exposure. In Study I, II and III, we 
used Poisson regression models to allow for the repeated measurement of outcomes during 
follow-up. The outcomes of interest were hospitalized injuries that could happen repeatedly in 
Study I and II, and recurrent health visits due to psychiatric disorders and cardiovascular 
diseases in Study III. Conditional Poisson regression model was used after stratifying by the 
matched clusters in within-individual comparison in Study I and III (156). In Study IV, we used 
Cox regression model, also known as proportional hazards regression model, to investigate the 
constant effect of NSAID use on unnatural deaths after cancer diagnosis. Assumption of 
proportional hazards was tested using Schoenfeld residuals and no major violation of such 
assumption was found.  
7.2.3 Bias and confounding 
Our studies benefited from the minimized potential biases in the large-scale register-based 
studies with information collected on an entire population prospectively and independently. 
Despite of the high quality of information from registers, some biases still need to be discussed 
considering their potential impact on result interpretation.  
Selection bias 
Selection bias can be introduced if the study sample is not representative of the population 
intend to be enrolled in analysis. In cohort study, selection bias is induced when included 
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participants in the beginning of follow-up are not representative of the study population, or 
individuals who are lost to follow-up or withdraw from the study are different from those who 
remain in the follow-up. In our studies, we used Swedish population and health registers to 
follow the entire population living in Sweden or Skåne region, which has largely eliminated 
the potential selection bias. Of note, Study II enrolled all women that participated in organized 
or opportunistic screening. Non-response to cervical cancer screening programme might lead 
to selection bias to some extent if a selected group did not participate in cancer screening, for 
instance, women with low socioeconomic status. The coverage of cervical cancer screening 
was however 82% in 2016 across the country (148). In Study II, the estimates were barely 
changed after adjusting for education and income. We therefore speculate that the impact from 
socioeconomic status is minimal on the results of Study II. In all studies, emigration was 
regarded as one censoring outcome. Because emigration represents a small proportion of 
censoring and is not evidently to be associated with the studied outcomes, it is unlikely that 
loss due to emigration would have introduced selection bias to a large extent.  
Information bias 
Information bias, also called observational bias or misclassification, should be considered when 
the measurement of exposure, outcome or confounders is not always accurate. In general, the 
extent of information bias in this thesis is likely small, considering the fact that all information 
on exposure, outcome and key variables is required from population-based regional or national 
registers, instead of, for example, from self-reported information, although the information 
from registers is not always complete and correct.  
Misclassification of exposure is less likely to occur in Study I, II and III, because of the almost 
complete coverage of newly diagnosed cancer from the Swedish Cancer Register, NKCx and 
SHR. Of note, date of diagnosis recorded in the Swedish Cancer Register represents by 
definition the date when the cancer diagnosis is determined clinically or through morphological 
examinations (18), not necessary when a patient is informed of the diagnosis. This recorded 
date in the register shall in most cases precede the date when patients are informed about the 
diagnosis. Another source of potential misclassification of exposure might be suspected in 
Study III, where women could be diagnosed with unspecified lump in breast before receiving 
a cancer diagnosis. Because time period before start of workup was counted to the reference 
group, it is possible that women with a breast cancer had previously been diagnosed with a 
lump and were misclassified as unexposed group before the workup for breast cancer. This 
might lead to a diluted association. In Study IV, the use of prescription text to quantify days on 
medication has largely eliminated the concern of misclassification of on- and off-medication 
periods. We however had no information from the register upon whether the patients in fact 
used the dispensed medications. This might result in an underestimation of the studied 
association as well. We conducted a sensitivity analysis to validate the definition for on- and 
off-medication period, by defining the first month after each on-medication period also as on-
medication period rather than off-medication period. We found no difference of the 
associations. 
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Surveillance bias, also called detection bias, may occur when some groups are followed up 
more closely than others, leading to a more frequent outcome reporting among those who have 
been monitored closely. In Study I and II, we chose to use injuries attended at inpatient care as 
the main outcome of interest since inpatient visits was less prone to surveillance bias. In Study 
III, we had the unique opportunity to use all levels of healthcare provided in Skåne region. The 
inclusion of primary care visits might introduce potential surveillance bias because women who 
were exposed to a cancer diagnostic workup were more likely to be diagnosed with other health 
problems, than women who were not exposed. It is possible that some of the observed 
associations were due to surveillance bias. However, the rate increase of cardiovascular 
diseases observed from specialist care visits, in addition to primary care visits, during the 
diagnostic workup of potential breast cancer, rejected the claim that surveillance bias explained 
completely the findings. It might also be noted that such bias can be introduced by using 
repeated outcome measurements in Study I, II and III. To assess such impact, we included the 
first outcome during each time period as the outcome definition in a sensitivity analysis of these 
studies, and the results confirmed largely the main findings.  
In Study IV, suicide is claimed to be a challenge in classifying causes of death, and can be 
misclassified as accidents (203). The misclassification of the suicidal outcome might have 
contributed to a lack of power to detect the true associations. 
Confounding 
The association between exposure and outcome can be distorted by confounding factors. By 
design, a within-individual comparison was used in Study I and III, which alleviated largely 
the concern of confounding factors that are fixed over time. In all analyses, we controlled for a 
couple of variables, including age, sex, calendar period, cohabitation status, socioeconomic 
status and history of preexisting diseases, which also eliminated the concern of confounding. 
However, residual confounding cannot be excluded. For instance, in Study III, the use of 
registered parish as proxy for socioeconomic status might induce residual confounding. We 
cannot completely roll out the impact from other factors, such as use of psychiatric medications, 
behaviour and other social support. In Study II, information on tumour stage was not available 
during the study period, and the potential contribution of cancer stage on the risk of injures 
among women with cervical cancer was not addressed. In Study III, we had little clinical 
information, including detailed reasons of workup initiation, type of symptoms, and course of 
diagnostic workup, on women that underwent a diagnostic workup. Such detailed information 
was not available in register. In Study IV, confounding by indication or indication bias may 
occur when the observed association is related to indication for medication but not the use of 
medication. To alleviate this concern, we contrasted findings between aspirin and non-aspirin 
NSAIDs. The different result pattern between these two groups alleviated greatly the concern 
of confounding by indication assuming that it would have functioned in a similar direction for 
both drugs.  
Generalizability 
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Many previous studies focused on highly selected participants, such as screened population 
from cancer screening programs, which is mostly likely to be well educated, higher in 
socioeconomic status, and healthier than the general population. Although our population-
based studies are considered to have a good external validity in generalizing the findings to the 
entire Swedish population, our results shall be generalized with caution to other populations, 
especially to populations with different health care system and cancer screening protocols.  
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8 CONCLUSIONS 
§ We found that patients with a cancer diagnosis had an increased rate of iatrogenic and 
non-iatrogenic injuries attended by inpatient care, both before and after cancer 
diagnosis. The findings provide first evidence on the burden of medical complications 
and call for prevention of self-harm and accidental injuries during the critical time 
period of cancer diagnosis and treatment.  
§ The diagnostic procedures during cervical screening are safe in terms of severe 
iatrogenic and non-iatrogenic injuries. Although women with invasive cervical cancer 
had an increased rate of non-iatrogenic injuries in relation to receiving a diagnosis of 
cervical cancer, severe iatrogenic and non-iatrogenic injuries was very rare during the 
diagnostic workup of women with cervical cancer and its precursor lesions. 
§ Women evaluated for a suspected breast cancer had an increased rate of psychiatric 
disorders and cardiovascular diseases when waiting for the diagnosis. These rate 
increase appeared to be stronger for a diagnostic workup that was due to symptoms 
compared to a workup that was due to screening findings. 
§ We found that aspirin intake was associated with a lower risk of unnatural deaths after 
a cancer diagnosis. We did not find an association between use of non-aspirin NSAIDs 
and risk of unnatural deaths. Our study provides therefore evidence for a beneficial 
effect of low-dose aspirin use in reducing such severe health outcomes after a diagnosis 
of cancer. 
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9 FUTURE PERSPECTIVES 
In Study I and II, we focused on injuries requiring inpatient care as the outcome of interest 
because severe outcomes are less prone to surveillance bias. Because 90% of the injuries 
occurred in the elderly population are mild conditions and associated with to later-onset of 
recurrent injuries (51), whether similar increased risk for injuries requiring only outpatient and 
primary care during the diagnostic process of cancer warrants further evaluation. By including 
all levels of healthcare visits, such as through using SHR in Study III, we might be able to study 
the full process of healthcare visit during cancer diagnostic workup, for example, the transfers 
between healthcare systems involving different healthcare professionals (150). Future studies 
with more detailed clinical information on the reason of cancer diagnostic workup, the course 
of an evaluation process, and the decision and action of treatment strategies including also non-
surgical treatment are needed.  
We found an increased risk of stress-related health outcomes when women were evaluated for 
a potential breast cancer. Whether or not similar results are seen for other cancer types remains 
largely unknown. Given the lower survival rate and the worse prognosis in other cancers 
compared to breast cancer, the health impact of psychological stress in relation to the diagnostic 
workup of other cancer types is likely to be more influential, for instance, for patients evaluated 
for a cancer with signs and symptoms that heavily affect quality of life. Studies are therefore 
needed to investigate the impact of cancer diagnostic workup among these patients.  
In this thesis, we found rate increase of different stress-related health outcomes when patients 
are evaluated for cancer. However, we could not disentangle the impact of psychological stress 
from the influence of cancer symptoms and pathophysiology. For example, cancer-related pain 
and tumor-induced inflammation may also contribute to the occurrence of a variety of health 
outcomes, when acting jointly with stress-induced inflammation. The underlying mechanisms 
are complex and the contribution of each part requires further investigation. It is possible that 
stress response may contribute to the initiation and progression of other diseases. We studied 
some selected health outcomes that are known to be stress-related, other health outcomes such 
as infection, autoimmune and metabolic diseases, could also be targeted in future research. 
Furthermore, given the highly stressful experience during cancer evaluation, it is plausible that 
the psychological burden induced by diagnostic workup may have an adverse impact on cancer 
survival in general and on patients’ quality of life specifically. So far, very little has been done 
in connecting the experience during cancer diagnostic workup to the long-term health 
outcomes. It can be speculated that patients who suffer from the diagnostic workup and 
therapeutic procedures may also be the individuals requiring more healthcare resources, sick 
leave days, and health reimbursement. 
We found that use of anti-inflammatory drugs was associated with a lower risk of unnatural 
deaths after a cancer diagnosis, reassuring the role of inflammation between stress and its 
related health outcomes. More studies are warranted to assess whether such medication use 
could also attenuate other non-fatal stress-related health outcomes. Meanwhile, future research 
is needed to identify other potential interventions, such as family and social support, in reducing 
health risks. A better understanding of the inflammatory pathway between stress and stress-
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related health outcomes may provide critical insights into mechanisms underlying a variety of 
stress-related health outcomes in cancer patients. It is of great value to figure out why 
vulnerability and stress resilience may differ between individuals, from both genetic and non-
genetic point of view. Last but not least, taking care of family members with severe diseases 
can also introduce a high level of psychological burden. Heath adversities in primary 
caregivers, such as parents, spouse and children of the patient, deserve additional attention both 
in research and clinically.  
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